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Epilepsy is a common neurological disorder that affects over 70 million people world-
wide. Despite the recent introduction of new antiseizure drugs (ASDs), about one-third 
of patients with epilepsy have seizures refractory to pharmacotherapy. Early identifica-
tion of patients who will become refractory to ASDs could help direct such patients 
to appropriate non-pharmacological treatment, but the complexity in the temporal 
patterns of epilepsy could make such identification difficult. The target hypothesis and 
transporter hypothesis are the most cited theories trying to explain refractory epilepsy, 
but neither theory alone fully explains the neurobiological basis of pharmacoresistance. 
This review summarizes evidence for and against several major theories, including the 
pharmacokinetic hypothesis, neural network hypothesis, intrinsic severity hypothesis, 
gene variant hypothesis, target hypothesis, and transporter hypothesis. The discussion 
is mainly focused on the transporter hypothesis, where clinical and experimental data 
are discussed on multidrug transporter overexpression, substrate profiles of ASDs, 
mechanism of transporter upregulation, polymorphisms of transporters, and the use 
of transporter inhibitors. Finally, future perspectives are presented for the improvement 
of current hypotheses and the development of treatment strategies as guided by the 
current understanding of refractory epilepsy.
Keywords: epilepsy, refractory epilepsy, blood–brain barrier, P-glycoprotein, transporter hypothesis, target 
hypothesis, transporter inhibition, transporter regulation
BACKGROUND: ReFRACTORY ePiLePSY
Epilepsy is a common and devastating neurological disorder, affecting more than 70 million people 
worldwide (1). Epilepsy patients have recurrent unprovoked seizures, which can be focal or general-
ized in nature (2, 3). As a first line of treatment, antiseizure drugs (ASDs) are routinely used to 
control seizures. However, about one-third of epilepsy patients suffer from uncontrolled seizures 
despite pharmacotherapy (4). Although a unifying and precise definition of “refractory epilepsy” is 
not available (5), an epilepsy is generally considered “refractory,” “drug-resistant,” or “intractable” 
when seizures cannot be controlled by at least two or three ASDs appropriate for the particular 
epilepsy type (6–9). In this regard, the International League Against Epilepsy (ILAE) Task Force 
proposed that “[d]rug-resistant epilepsy may be defined as failure of adequate trials of two tolerated 
and appropriately chosen and used ASD schedules (whether as monotherapies or in combination) 
to achieve sustained seizure freedom” (10).
TABLe 1 | Success rates of achieving seizure freedom with successive 
antiseizure drug (ASD) regimens.
Number of 
ASDs
Number of 
patients
Number of 
seizure-free 
patients
Seizure-free patients 
(% of total cohort)
1 1,098 543 49.5
2 398 146 13.3
3 168 41 3.7
4 68 11 1.0
5 32 4 0.4
6 16 2 0.2
7 9 2 0.2
8 3 0 0
9 2 0 0
The chance of seizure freedom declines with successive ASD regimens, most markedly 
from the first to the third, among patients with epilepsy. Modified from Brodie et al. (19).
FiGURe 2 | Treatment strategies for refractory epilepsy. Current treatment 
options for patients with refractory epilepsy include pharmacotherapy with 
antiseizure drugs, surgical removal of the seizure focus, and alternative 
approaches such as neurostimulation, ketogenic diet, and lifestyle changes.
FiGURe 1 | Effect of refractory epilepsy on patients’ quality of life. The circles 
depict the impact of recurrent seizures on the quality of life of patients with 
refractory epilepsy.
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Refractory epilepsy is associated with increased morbidity 
and mortality, serious psychosocial consequences, cognitive 
pro blems, and reduced quality of life (Figure  1) (11–13). 
Despite the introduction of many new ASDs since 1990s, there 
has been little improvement in the prognosis of common epi-
lepsies and childhood epilepsy syndromes (14, 15). This is not 
surprising given the lack of compelling evidence supporting the 
superiority of new ASDs over older ones, as well as the small 
placebo-corrected efficacy of adjunctive treatment with modern 
ASDs (16, 17).
As part of this background section on refractory epilepsy, we 
will briefly cover management, temporal patterns, and predictors 
of refractory epilepsy, and then discuss the existing hypotheses 
that have been proposed to explain the potential mechanisms 
underlying ASD resistance.
Management of Refractory epilepsy
Patients with refractory epilepsy carry the greatest burden of 
treatment of epilepsy (18). Management strategies of refrac-
tory epilepsy fall into three main categories: pharmacotherapy, 
epilepsy surgery, and alternative treatment strategies including 
neurostimulation, ketogenic diet, and lifestyle changes (Figure 2) 
(18). With regard to pharmacotherapy, clinical evidence shows 
that patients who do not respond to two ASDs have only a small 
chance to control their seizures with any additional administered 
ASD (10). In a recently published prospective cohort study with 
1,098 newly diagnosed epilepsy patients who were recruited 
between 1982 and 2006 and were followed for up to 26 years (until 
2008), Brodie et  al. (19) found that 49.5% of enrolled patients 
remained seizure-free (i.e., not experiencing seizures for at least 
1  year) on their first ASD, while only 13.3, 3.7, 1.0, and 0.4% 
of the cohort became seizure-free on the second, third, fourth, 
and fifth regimen (either as monotherapy or in combination), 
respectively (Table 1). However, since a few patients did achieve 
sustained seizure freedom while on the fourth up to the seventh 
medication regimen, patients who failed the first three ASD 
regimens did not inevitably become refractory (19).
In patients with refractory epilepsy who do not respond to 
ASDs, other therapeutic avenues are pursued including surgery 
(18). In this regard, patients with refractory epilepsy caused by 
distinct resectable lesions, such as hippocampal sclerosis (HS), 
are potential candidates for neurosurgical removal of the lesion 
(20). Epilepsy surgery has been shown to be superior to the con-
tinued use of ASDs, but the supporting clinical evidence from 
randomized controlled trials is limited to temporal lobe epilepsy 
(TLE) (21).
An alternative treatment approach is neurostimulation 
such as vagus nerve stimulation and responsive neurostimula-
tion (22). Vagus nerve stimulation can reduce the frequency 
and/or severity of seizures (20), but some patients experience 
adverse effects such as hoarseness, coughing, and dyspnea (23). 
Responsive neurostimulation is a novel treatment that was 
approved in the US in 2013 for adults with focal onset epilepsy 
(23). Neurostimulation is an invasive, intracranial procedure, 
and its efficacy does not significantly differ from other neuro-
stimulation treatments (22).
Another option is to switch to a ketogenic diet, an approach 
that is more commonly used in children with refractory epilepsy 
and, while the underlying mechanism remains unknown, has 
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demonstrated high efficacy rates with some studies showing that 
about half the patients had a more than 50% reduction in seizure 
numbers (23). However, ketogenic diet is challenging for children 
due to compliance difficulties and potential short-term and long-
term adverse effects and, therefore, requires regular follow-up 
and clinical supervision (24).
Finally, certain lifestyle changes can help to control seizures 
by minimizing seizure triggers. Common seizure triggers include 
sleep deprivation, interrupted sleep, longer periods without food, 
alcohol, caffeine, nicotine, drugs of abuse, psychological stress, 
emotional tension, and sensory input (e.g., photosensitivity, 
strobe light, and computer and video games). Therefore, sufficient 
sleep, managing stress levels effectively, and following a healthy 
lifestyle can help with seizure control to some extent.
In summary, pharmacotherapy is the mainstay of epilepsy 
management. Epilepsy surgery and alternative measures includ-
ing neurostimulation and ketogenic diet are among the therapeu-
tic options for patients with refractory epilepsy, each with its own 
advantages and disadvantages. While seizures cannot fully be 
prevented by lifestyle changes alone, these changes can contribute 
to improving quality of life and helping with seizure control. For 
treatment purposes, each patient’s unique circumstances need 
to be taken into consideration when selecting the appropriate 
management strategy (18).
Temporal Patterns of Refractory epilepsy
Pharmacoresistance in epilepsy was thought to be constitutive or 
progressive, and consequently, one clinical paradigm postulated 
that an early response to ASD therapy indicates a favorable prog-
nosis (25). However, accumulating evidence now demonstrates 
a higher level of complexity of the temporal patterns of epilepsy, 
i.e., the clinical courses and response patterns to ASDs (15). In the 
cohort study of Brodie et al. (19), 37% (408 patients) of a total of 
1,098 epilepsy patients achieved sustained seizure freedom within 
6 months of initiating ASD therapy, 22% of patients achieved sus-
tained seizure freedom that was delayed for over 6 months after 
treatment initiation, 16% of patients fluctuated between seizure 
freedom and relapse, and 25% of patients never achieved seizure 
freedom for at least 1 year. Of the 408 patients who followed the 
first temporal pattern, the majority became seizure-free on the 
first monotherapy regimen, 37 required a second regimen (either 
an alternative monotherapy or combination regimen), and 4 
required a third regimen (19). Callaghan et  al. (26) conducted 
a prospective cohort study with 246 ASD-resistant patients and 
found that on average 5% of patients per year gained seizure 
freedom for at least 1 year over 6 years of follow-up, but the risk 
of relapse among those patients was relatively high with 71% after 
5 years. The authors of the study also noted that the remission 
was negatively correlated with the number of ASDs that failed 
in a particular patient, while relapse could not be explained by 
dose reductions or medication discontinuation alone. Similarly, 
Neligan et  al. (27) conducted a prospective cohort study in 
139 patients with uncontrolled chronic epilepsy with a median 
follow-up of 6.9 years and showed that 19% of patients became 
seizure free and 29% of patients experienced 50–99% improve-
ment in seizure frequency at the last follow-up. However, a 
substantial proportion of the patients who experienced remission 
subsequently relapsed (27). In another study, Neligan et al. (28) 
found that the intermittent pattern of seizures (i.e., having one 
or more seizure-free periods which lasted for at least 2  years) 
occurred in about 30% of patients with refractory epilepsy, which 
was found to be associated with fewer total ASDs taken and lower 
seizure frequency in the previous year when compared to the 
continuous pattern of pharmacoresistance.
In summary, recent studies have shown that the temporal 
patterns of refractoriness in epilepsy are more complex than 
previously assumed, and up to 30% of patients with refractory 
epilepsy follow a fluctuating course with periods of remission and 
relapse. Based on these observations, achievement of sustained 
seizure freedom may be a result of both the development course 
of benign epilepsy and the treatment effect of ASDs, but it is 
unclear at this point how much each of the two contributes to 
long-term remission (28).
Predictors of ASD Resistance
Some have suggested that early identification of epilepsy patients 
who will become refractory to ASDs could help directing these 
patients to appropriate non-pharmacological treatment (3, 9, 29). 
However, others have argued that such identification can be 
difficult given that a considerable number of patients may have 
alternating periods of relapse and remission (22). Nevertheless, 
outcome studies in epilepsy have identified several factors that 
have repeatedly been shown to be predictive of a poor prognosis, 
including the initial response to pharmacotherapy, the underly-
ing etiology, and a patient’s history of seizure frequency (3). 
Specifically, inadequate response to initial ASD therapy has been 
shown to be the most powerful indicator of refractory epilepsy 
(3, 4). Symptomatic epilepsy characterized by structural brain 
abnormality tends to be more ASD-resistant than idiopathic 
epilepsy, which presumably has an underlying genetic basis 
(13, 29). A high frequency of pretreatment seizures has also been 
found to be a poor prognostic factor. On the other hand, factors 
such as seizure types and electroencephalogram findings did not 
consistently show significant prognostic value (3).
Together, prognostic factors are useful in predicting refractori-
ness in some but not all patient cases (29), and more importantly, 
none of these factors explains the underlying mechanism of 
pharmacoresistance (6, 11).
POTeNTiAL MeCHANiSMS OF ASD 
ReSiSTANCe
Understanding the mechanism(s) underlying ASD resistance 
has the potential to help the development of more effective 
therapeutic options for patients with refractory epilepsy. The 
target hypothesis and transporter hypothesis are the most 
cited theories of ASD resistance, but neither fully explains the 
neurobiological basis of this phenomenon (30, 31). It is clear 
that the mechanism(s) of refractory epilepsy is/are most likely 
multifactorial, involving environmental, genetic, as well as dis-
ease- and drug-related factors (32, 33). In the following sections, 
we discuss several hypotheses that have been proposed, starting 
with the least cited to the most cited: (1) the pharmacokinetic 
FiGURe 3 | Overview of proposed hypotheses for possible underlying mechanism(s) of antiseizure drug (ASD) resistance. (1) The Pharmacokinetic Hypothesis 
proposes that overexpression of drug efflux transporters in peripheral organs decreases ASD plasma levels, thereby reducing the amount of ASD available to enter 
the brain and reach the epileptic focus. (2) The Neuronal Network Hypothesis states that seizure-induced degeneration and remodeling of the neural network 
suppresses the brain’s seizure control system and restricts ASDs from accessing neuronal targets. (3) The Intrinsic Severity Hypothesis proposes that common 
neurobiological factors contribute to both epilepsy severity and pharmacoresistance (30). (4) The Gene Variant Hypothesis states that variations in genes associated 
with ASD pharmacokinetics and pharmacodynamics cause inherent pharmacoresistance. These genes include metabolic enzymes, ion channels, and certain 
neurotransmitter receptors that are targets for ASDs. (5) The Target Hypothesis postulates that alterations in the properties of ASD targets, such as changes in 
voltage-gated ion channels and neurotransmitter receptors (e.g., GABAA receptor), result in decreased drug sensitivity and thus lead to refractoriness. (6) The 
Transporter Hypothesis states that overexpression of ASD efflux transporters at the blood–brain barrier in epilepsy leads to decreased ASD brain uptake and thus 
ASD resistance.
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hypothesis, (2) the neural network hypothesis, (3) the intrinsic 
severity hypothesis, (4) the gene variant hypothesis, (5) the target 
hypothesis, and finally the (6) transporter hypothesis, which will 
be the main focus of this review (Figure 3).
Pharmacokinetic Hypothesis
The pharmacokinetic hypothesis proposes that overexpression 
of efflux transporters in peripheral organs such as intestine, liver, 
and kidney decreases ASD plasma levels in refractory epilepsy 
patients, thereby reducing the amount of ASD available to cross 
the blood–brain barrier and reach the epileptic focus in the 
brain (34).
In a case report of a pediatric patient with refractory epilepsy, 
Lazarowski et al. (35) detected persistently low plasma levels of 
carbamazepine, phenytoin, and valproic acid. This coincided 
with increased P-glycoprotein (P-gp) protein expression levels 
in endothelial cells, astrocytes, and neurons from the patient’s 
resected brain tissue. In another case report of a pediatric patient 
with refractory epilepsy, the same group described persistently low 
phenytoin plasma levels and increased P-gp protein expression 
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analyzed by immunohistochemistry in resected epileptic brain 
tissue (36). The authors also reported that the P-gp sub strate, 
99mTc-hexakis-2-methoxyisobutylisonitrile, demonstrated increased 
hepatic clearance in eight patients with refractory epilepsy com-
pared to seven normal subjects and four patients with controlled 
epilepsy (37). Based on this finding, the authors postulated that 
the liver is involved in potential pharmacokinetic changes that 
could contribute to ASD resistance (34).
In the two cases described above, the authors argued that 
subtherapeutic ASD blood levels could not be explained by over-
expression of P-gp at the blood–brain barrier and in neurons. 
Instead, the authors suggested overexpression of P-gp or other 
efflux transporters in the periphery as an additional mechanism 
for refractory epilepsy, especially in patients who presented with 
persistently low ASD plasma levels (34). While this explanation 
is plausible, the authors postulated their hypothesis based on only 
two case studies, and it is unclear at this point if their observa-
tion is limited to these cases or a wider-spread phenomenon. In 
addition, the authors did not provide any additional evidence 
from human samples and/or from rodent epilepsy models to 
substantiate their statements.
Support for the pharmacokinetic hypothesis also comes from 
studies showing persistent low ASDs levels in patients with refrac-
tory epilepsy regardless of P-gp overexpression. For example, in a 
clinical study of 70 patients treated with oral phenytoin, Iwamoto 
et al. (38) found that the mean free phenytoin plasma concentra-
tion was significantly higher in patients with a complete response 
to phenytoin compared to patients with a partial response. This 
effect was independent of the phenytoin dose, and the results 
suggest that the free phenytoin concentration could be useful 
for monitoring ASDs effects in patients receiving phenytoin 
monotherapy. In a retrospective study, Paul and coworkers (39) 
found in 80% of patients with refractory epilepsy that lamotrigine 
serum levels were decreased by 20% after surgery compared to 
preoperative levels. In six patients, seizures were observed within 
the first 2 weeks after surgery. In three of these patients, seizures 
occurred after reaching the nadir of lamotrigine plasma levels. 
Therefore, the authors propose counteracting a postoperative 
reduction in serum lamotrigine levels by augmenting the pre-
operative drug dose and close monitoring of drug serum levels 
after surgery (39). Dalaklioglu (40) reported a high frequency 
of subtherapeutic ASD plasma levels in patients with refractory 
epilepsy. Further, Fagiolino et al. (41) conducted a clinical study 
and observed that the saliva drug concentration ratio from two 
sequentially collected samples could be utilized to detect systemic 
clearance changes. This could be useful to predict plasma levels 
of ASDs such as carbamazepine and phenytoin that are known to 
induce drug efflux transporters during chronic treatment.
Other studies suggest an association between peripheral 
expression levels of metabolizing enzymes and efflux transporters 
on the one hand and plasma ASD concentrations on the other 
hand. Kerb et al. (42) reported a clinical study conducted in 96 
healthy Turkish volunteers. In this study, the combined analysis of 
CYP2C9 and multidrug resistance protein 1 (MDR1) genotypes 
had better predictive value for phenytoin plasma concentra-
tions than CYP2C9 analysis alone. Simon et al. (43) found that 
increased intestinal P-gp expression levels had a weak association 
with low carbamazepine plasma concentrations, and increased 
intestinal MRP2 expression levels were weakly related to high 
carbamazepine doses in 29 epilepsy patients. Nevertheless, 
unlike the case reports by Lazarowski et al., neither study directly 
addressed ASD response.
In addition, data from clinical studies show that ASD-
responsive and ASD-resistant patients display adverse events to 
the same extent (44, 45), suggesting similar plasma ASD levels in 
the two groups of patients. One explanation for this observation is 
that efflux transporter overexpression is restricted to the epileptic 
focus. This observation also suggests that same plasma ASD con-
centrations are due to same enzyme and transporter expression 
levels in peripheral organs. While both of these explanations are 
plausible, one does not necessarily lead to the other.
Furthermore, some animal studies do not support the phar-
macokinetic hypothesis. In these studies, differences in ASD 
plasma concentrations and/or side effects have not been observed 
between ASD responders and non-responders (46, 47), and 
administration of transporter inhibitors enhanced anticonvul-
sant activity of the ASD without changing its pharmacokinetics 
(44, 47, 48).
Together, the pharmacokinetic hypothesis of refractory epi-
lepsy as a stand-alone theory is difficult to validate. One can 
argue that because abnormalities in ASD plasma concentrations 
can be readily captured by therapeutic drug monitoring, phar-
macokinetic variability is probably not a major contributor to 
pharmacoresistance in situations where ASD doses are adjusted 
accordingly. This argument, however, is further complicated 
because therapeutic ASD plasma concentrations vary among 
patients, and no one specific therapeutic ASD concentration 
range is applicable to all patients (49, 50). The optimal plasma 
concentration for a patient is partially related to the patient’s 
seizure type and disease severity, as well as the pharmacodynamic 
characteristics of the specific ASD(s) used (49, 50). For newer 
ASDs, wide ranges of therapeutic serum concentrations have 
also been reported, and concentrations corresponding to toxicity 
and non-response can overlap considerably (50). Therefore, it 
seems more appropriate to adjust ASD dosages on an individual 
basis than to strictly conform to reference therapeutic plasma 
concentrations (49).
Neural Network Hypothesis
Recently, Fang et al. (51) proposed the neural network hypothesis, 
which states that seizure-induced degeneration and remodeling 
of the neural network suppress the endogenous antiseizure 
system and inhibit ASDs from accessing neuronal targets. 
Specifically, molecular evidence shows that the growth cone at 
the tip of an exon receives abnormally expressed guidance and 
signaling molecules in the epileptic brain (51). In addition, the 
formation of new excitatory circuits as a result of progressive 
sprouting has been widely investigated in TLE (51). The authors 
postulate that neurogenesis and astrogliosis in TLE could con-
tribute to the development of abnormal neural networks and 
eventually ASD resistance. However, the major weakness of this 
hypothesis is that alterations in the neural network do not lead 
to refractoriness in all epilepsy patients, and therefore, further 
biological evidence on potential differences in the changes of 
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brain plasticity between drug-responsive and drug-resistant 
epilepsy is needed to support this hypothesis (51).
intrinsic Severity Hypothesis
The intrinsic severity hypothesis states that common neurobio-
logical factors contribute to both epilepsy severity and pharma-
coresistance (30). In other words, pharmacoresistance is inherent 
to the disease severity, which could exist on a continuum ranging 
from mild to severe (52).
In this regard, data from reports supporting the intrinsic 
severity hypothesis suggest that high pretreatment seizure fre-
quency is an important predictor for refractory epilepsy (53–55). 
Based on these reports, it is tempting to draw an association 
between ASD resistance and the experimental electrical kindling, 
in which repeated electrical stimulation at a subconvulsive level 
can eventually induce spontaneous recurrent seizures in animals 
(4, 13). However, a randomized clinical study demonstrated 
that starting ASD treatment after the first tonic–clonic seizure 
did not improve the prognosis of epilepsy (56). In fact, the same 
probability of becoming seizure-free for 1 or 2 years was seen in 
patients who were treated after the first seizure and those who 
received treatment after seizure recurrence (56). A similar con-
clusion was drawn from a cohort study in children with epilepsy, 
which showed that ASD administration at some point during the 
first 10 seizures had no aggravating effect on achieving seizure 
control or early remission (57). In a randomized study in 1,847 
epilepsy patients, the authors compared immediate and deferred 
treatment with ASDs and found that immediate treatment 
was associated with seizure reduction in the first 1–2 years, but 
rates of long-term remission did not differ between the two 
groups (58).
Therefore, such findings argue against the notion of a kind ling-
like process where the likelihood of ASD resistance is increased 
with the number of pretreatment seizures. Instead, high seizure 
frequency prior to ASD treatment could be the result of patho-
physiological changes characterizing refractory epilepsy (4). An 
alternative interpretation of the epidemiological data resulted 
in the intrinsic severity hypothesis. While this theory appears 
biologically plausible, it does not adequately apply to epilepsy 
types that demonstrate a fluctuating or evolving pattern of ASD 
resistance (30). In addition, there is little evidence supporting a 
direct mechanistic link between the severity of epilepsy and ASD 
response (59). Therefore, it has been suggested that the intrinsic 
severity theory alone does not sufficiently explain pharmacore-
sistance in epilepsy (59).
Gene variant Hypothesis
The gene variant hypothesis states that variations in genes associ-
ated with ASD pharmacokinetics and pharmacodynamics cause 
inherent pharmacoresistance (17). Specifically, variations in 
genes that encode enzymes that metabolize ASDs or ion channels 
and neurotransmitter receptors targeted by ASDs can potentially 
affect ASD response (33).
Phenytoin is metabolized by CYP2C9 (90%) and CYP2C19 
(60). Van der Weide et  al. (61) reported strong associations 
between the low activity alleles of CYP2C9 (CYP2C9*2 and 
CYP2C9*3) and a reduced phenytoin dose requirement. In a 
different study, Tate et al. (60) also revealed a significant correla-
tion between CYP2C9*3 and a reduced dose requirement of phe-
nytoin, and Ufer et al. (62) found in a specific subgroup of patients 
significantly more heterozygous CYP2C8*4 and CYP2C9*3 
variant allele carriers among ASD responders compared to ASD 
non-responders.
Voltage-gated sodium channels are the target of several com-
monly used ASDs, including carbamazepine, phenytoin, lamo-
trigine, and valproate (63). Voltage-gated sodium channels consist 
of one α subunit and two β subunits. The isoforms of the α subunits, 
Nav1.1, 1.2, 1.3, and 1.8, are encoded by the SCN1A, 2A, 3A, and 
8A genes, respectively (64). Using a haplotype-tagging strategy, 
Tate et al. (60) demonstrated a significant correlation between an 
intronic single nucleotide polymorphism (SNP) in the SCN1A  
gene (IVS5-91G>A or rs3812718) and the maximum required 
doses of carbamazepine and phenytoin in groups of 425 and 281 
English patients, respectively. In a follow-up study in 168 Chinese 
epilepsy patients on phenytoin treatment, Tate et al. (65) found 
that the same polymorphism was correlated with phenytoin 
serum levels at maintenance dose, but not with the maintenance 
or maximum dose of phenytoin. In a study including 228 Japanese 
patients with epilepsy, Abe et al. (66) demonstrated a significant 
association between the frequency of the SCN1A IVS5-91 AA 
genotype and resistance to carbamazepine, but not the carbamaz-
epine maximum or maintenance dose. Kwan et al. (64) genotyped 
tagging and candidate SNPs of SCN1A, 2A, and 3A in 471 Chinese 
patients with epilepsy and reported a significant correlation 
between an intronic SNP in SCN2A (IVS7-32A>G, rs2304016) 
and responsiveness to various ASDs, but the polymorphism did 
not significantly alter SCN2A mRNA levels in resected brain tissue 
or peripheral white blood cells. On the other hand, the associa-
tion between IVS5-91G>A in the SCN1A gene and ASD response 
was not observed in this study (64). Several more recent studies 
explored the relationship between other SNPs in the sodium 
channel genes and drug response in epilepsy, including SCN1A 
c.3184 A>G (rs2298771) and SCN2A c.56 G>A (rs17183814), 
both of which were found to be functionally significant in 
some neurological disorders (67–69). In a study including 336 
epilepsy patients from the northern part of India, Lakhan et al. 
(67) reported a significant association between the variant allele 
frequency of SCN2A c.56 G>A SNP and ASD resistance. This 
finding was confirmed by Kumari et al. (68) in another study with 
402 epilepsy patients from the same geographic region. Although 
Lakhan et  al. and Kumari et  al. did not reveal an association 
between SCN1A c.3184 A>G SNP and ASD resistance, Abo El 
Fotoh et al. (69) demonstrated a significant relationship between 
the AG genotype or G allele and ASD resistance in Egyptian 
children with epilepsy.
In summary, with the gene variant hypothesis, currently the 
strongest evidence exists for the association between CYP2C9 
polymorphism and phenytoin dose requirement. Although the 
relationship between various SCN1A and SCN2A polymorphisms 
and ASD dose requirement and/or response has been explored 
in a number of genetic association studies, the study results have 
been inconsistent, and genetic associations identified so far need 
further confirmation in larger populations. In addition, given 
the low frequency of certain alleles and the multifactorial nature 
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of refractory epilepsy, it is possible that individual markers may 
not have a large enough clinical impact on overall ASD response 
(64). Together, the impact of the gene variant hypothesis as a 
stand-alone theory is mainly limited by inconsistencies and poor 
reproducibility of study findings. Nevertheless, improvement in 
genomic technologies and research methodology is expected to 
increase the chances of uncovering truly predictive genetic mark-
ers for ASD resistance and further the advancement of epilepsy 
pharmacogenomics (70).
Target Hypothesis
The target hypothesis of refractory epilepsy postulates that 
alterations in the properties of ASD targets, such as composi-
tional changes in voltage-gated ion channels and neurotransmit-
ter receptors, result in decreased drug sensitivity and thus lead 
to refractoriness (63, 71). For example, loss of use-dependent 
blockade of voltage-gated sodium channels in dentate granule 
cells by carbamazepine was observed in rats after pilocarpine-
induced epilepsy and in resected hippocampal tissue from 
patients with carbamazepine-resistant TLE (71). However, this 
loss in efficacy due to a potential change in the molecular target 
has so far only been reported for carbamazepine and has not been 
demonstrated to occur with other ASDs that block sodium chan-
nels (72). Reduced sensitivity of GABAA receptors to agents that 
bind to the benzodiazepine receptor site 1 has been reported in 
the pilocarpine model of epilepsy (63), and data from two other 
studies showed changes in GABAA receptor subtypes in brain tis-
sue from patients with refractory TLE (73, 74). Overall, evidence 
supporting the target hypothesis mainly describes the loss of 
use-dependent channel blockade by carbamazepine and comes 
from resected human brain tissue (72, 75). The fact that most 
refractory patients are resistant to several ASDs acting on differ-
ent therapeutic targets undermines the general utility of the target 
hypothesis and instead supports the existence of a mechanism 
non-specific to individual ASDs (2).
Transporter Hypothesis
Multidrug resistance due to efflux transporters has been studied 
extensively in tumor cells. The best understood efflux transport-
ers are members of the ABC (ATP-binding cassette) superfamily 
subfamilies B, C, and G, specifically P-gp (ABCB1 or MDR1), 
the multidrug resistance-associated proteins (MRP1, ABCC1; 
MRP2, ABCC2), and breast cancer resistance protein (BCRP, 
ABCG2) (75). Members of the ABC superfamily are ATP-driven 
membrane pumps that actively transport substrates, including 
a large number of therapeutic drugs, against their concentra-
tion gradient out of cells and tissues, limiting their entry into 
the respective organs and thereby causing resistance (75). For 
example, P-gp, BCRP, and some multidrug resistance-associated 
proteins (MRPs) hinder chemotherapeutic drugs from entering 
cancer cells. Thus, ABC transporter overexpression in cancer 
causes resistance to chemotherapeutic drugs resulting in poor 
prognosis in cancer patients (32, 76).
In 1995, Tishler et  al. (77) found that MDR1 mRNA was 
overexpressed in brain tissue resected from patients with 
refractory epilepsy and postulated the transporter hypothesis 
of refractory epilepsy: P-gp overexpression at the blood–brain 
barrier in epilepsy decreases ASD brain uptake, thus causing 
ASD resistance similar to pharmacoresistance in cancer (2). 
Since this initial proposal by Tishler et al., other ABC transport-
ers have been shown to be upregulated at the blood–brain barrier 
in epilepsy and the transporter hypothesis has been intensively 
investigated (45). The transporter hypothesis is based on two 
assumptions: (1) overexpression of efflux transporters correlates 
with pharmacoresistance in epilepsy and (2) ASDs are subject to 
active transport by efflux transporters (78). In the following, we 
will describe the roles P-gp, the MRPs, and BCRP have in epilepsy 
in more detail.
P-Glycoprotein
P-glycoprotein is also known as MDR1 (old nomenclature) 
or ATP-binding cassette subfamily B member 1 (ABCB1, new 
nomenclature). P-gp is encoded by the MDR1 (ABCB1) gene in 
humans and by the mdr1a/mdr1b genes in rodents (79). P-gp pro-
tein is expressed in various barrier and excretory tissues such as 
intestine, liver, and kidney, where it actively exports hydrophobic 
and amphipathic molecules from the inside of cells or membranes 
to the outside (80, 81). This physiological function of export-
ing naturally occurring toxins and xenobiotics is considered 
to be a critical defense mechanism (82). In the normal human 
brain, P-gp is expressed in the luminal plasma membrane of the 
brain capillary endothelial cells that constitute the blood–brain 
barrier as well as in the apical membrane (facing the cerebro-
spinal fluid) of the choroid plexus epithelial cells that form the 
blood–cerebrospinal fluid barrier (83). P-gp expression is only 
marginally detectable in neurons or glial cells under normal, 
physiological conditions (32). In rodents, the mdr1a isoform is 
mainly expressed in endothelial cells of the blood–brain barrier, 
and mdr1b is primarily found in astrocytes (84).
Multidrug Resistance-Associated Proteins
The MRP family (ATP-binding cassette subfamily C, ABCC) 
comprises nine members (MRPs 1–9 or ABCCs 1–6 and 10–12) 
(85). MRPs are expressed in the membranes of various cell types, 
such as hepatocytes, kidney proximal tubular epithelial cells, 
enterocytes, and brain endothelial cells, where they transport a 
wide variety of mostly anionic endogenous and exogenous com-
pounds and their metabolites (85). The luminal and/or basolateral 
localization of MRP proteins is often specific to a certain cell type 
(86). MRP1 is expressed at the basolateral membrane of choroid 
plexus epithelial cells and at low levels at the luminal membrane 
of endothelial cells at the blood–brain barrier (86). MRP2 is 
exclusively expressed at the luminal membrane of polarized cells, 
including brain endothelial cells (85). MRP4 and MRP5 have 
also been found to be apically localized in human brain capillary 
endothelial cells (87), whereas neuronal or glial MRP1 and MRP2 
expression in the normal brain has not been consistently reported 
in the literature (32, 83, 88).
Breast Cancer Resistance Protein
Breast Cancer Resistance Protein (ATP-binding cassette subfam-
ily G member 2 or ABCG2) is prominently expressed at the apical 
membrane in various cell types, including hepatocytes, intestinal 
epithelial cells, kidney proximal tubular cells, and the endothelial 
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cells of the blood–brain barrier (76, 89). Similar to P-gp, BCRP 
transports a wide variety of substrates, and its tissue distribution 
contributes to its important roles in restricting absorption and 
facilitating elimination of drugs and xenobiotics (76).
Overexpression of Efflux Transporters in Refractory Epilepsy
P-glycoprotein overexpression in epileptogenic brain tissue 
in patients with refractory epilepsy has been documented in 
numerous studies (45). Tishler et al. (77) were the first to dem-
onstrate overexpression of MDR1 mRNA in 11 out of 19 resected 
brain specimens from patients with refractory focal epilepsy. 
Subsequently, increased levels of P-gp protein expression have 
also been observed in the brain capillary endothelium of resected 
brain tissue from patients with refractory epilepsy, where P-gp 
overexpression was localized to the luminal membrane of the brain 
capillary endothelium by immunohistochemistry (80, 90). P-gp 
overexpression was also detected in astrocytes and/or dysplastic 
neurons in common pathological causes of refractory epilepsy, 
including dysembryoplastic neuroepithelial tumors (DNT), HS, 
and focal cortical dysplasia (FCD) (32, 84, 88, 91–93).
MRP1 overexpression in astrocytes and/or dysplastic neurons 
in HS, DNT, and FCD has also been described in a number of 
studies (32, 88, 91, 93). The results from these studies confirm that 
MRP1 protein expression levels in astrocytes and neurons from 
brain tissue of epilepsy patients are significantly increased com-
pared to brain tissue from healthy individuals, while endothelial 
MRP1 expression did not differ between the two (94).
Dombrowski et al. (80) were the first to report increased MRP2 
and MRP5 mRNA levels in endothelial cells isolated from epileptic 
brain tissue of patients with refractory epilepsy compared to con-
trol endothelial cells from human umbilical vein and aneurysm 
domes. Aronica et al. (88) reported MRP2 protein overexpression 
in endothelial cells and astrocytes in HS tissue specimens of 
adult patients with TLE. The same observation was reported by 
Vogelgesang et  al. (92) for MRP2 protein in DNT tissue from 
patients with refractory epilepsy. In the same study, the authors 
also observed MRP5 protein overexpression in dysplastic neurons, 
astrocytes, and brain endothelial cells in epileptogenic tissue.
Data from few studies comparing BCRP expression in control 
and epileptic human brain tissue demonstrated the constitutive 
expression of BCRP in the brain capillary endothelium, but these 
data do not show differences in BCRP expression levels between 
the groups (89, 90, 92, 95). Due to the current lack of evidence 
on BCRP overexpression in human epileptic brain tissue, BCRP 
is unlikely a major player in ASD resistance as proposed by the 
transporter hypothesis.
Although increased mRNA and protein expression levels of 
P-gp and MRPs have been demonstrated in resected brain tissue 
from patients with ASD-resistant epilepsy, previous studies did 
not include proper controls, as it is generally difficult to obtain 
brain tissue from either patients with drug-responsive epilepsy or 
from healthy subjects without brain disease. Therefore, it is still 
unclear if overexpression of efflux transporters correlates with and 
potentially causes ASD resistance, or if it is an epiphenomenon 
of epilepsy in humans that is unrelated to ASD resistance (96).
In this regard, Volk and Löscher established a correlation 
between ASD response and P-gp expression levels in a rat model 
of TLE with sustained spontaneous recurrent seizures developed 
after electrically induced status epilepticus (SE) (46). Using this 
model, the authors demonstrated that epileptic rats that did not 
respond to phenobarbital had higher P-gp expression levels in 
the capillary endothelial cells of the limbic brain region com-
pared to rats that responded to phenobarbital (46). In humans, 
non-invasive positron emission tomography (PET) imaging is 
one approach to directly compare P-gp functional activity in 
ASD-responsive vs. ASD-resistant patients by determining tis-
sue concentrations of PET tracers that are P-gp substrates (97). 
In a small pilot PET study using the P-gp substrate (R)-[11C]
verapamil, Langer et al. (98) reported no significant differ ences 
in pharmacokinetic parameters between epileptogenic and non-
epileptogenic brain regions in patients with refractory uni lateral 
TLE. Subsequently, Feldmann et al. (99) conducted a PET study 
in 14 patients with ASD-refractory TLE, 8 patients with ASD-
controlled TLE, and 13 healthy control individuals. In patients 
with refractory TLE, (R)-[11C]verapamil brain uptake was 
reduced compared to seizure-free patients, and the increase in 
(R)-[11C]verapamil brain uptake following the administration 
of tariquidar (P-gp inhibitor) was smaller compared to healthy 
individuals; both observations are consistent with higher P-gp 
activity at the blood–brain barrier in patients with refractory TLE 
(99). This study was the first to provide direct in vivo evidence of 
P-gp overactivity in patients with refractory epilepsy. In a more 
recent study of Shin et al. (100) in six patients with ASD-resistant 
epilepsy, five patients with ASD-responsive epilepsy, and eight 
healthy subjects, (R)-[11C]verapamil PET and magnetic resonance 
(MR) imaging with cyclosporine A (P-gp inhibitor) demonstrated 
significant asymmetry of P-gp expression in refractory patients 
compared to both seizure-free patients and healthy subjects, 
suggesting higher P-gp expression and lower uptake of (R)-[11C]
verapamil in the group of patients with refractory epilepsy. Larger 
PET studies comparing transporter activity at the blood–brain 
barrier in ASD-responsive and ASD-resistant patients are needed 
in the future to confirm the results presented above.
In summary, overexpression of ABC multidrug efflux trans-
porters at the blood–brain barrier observed in numerous studies 
forms the foundation of the transporter hypothesis of refractory 
epilepsy. In addition, astrocytic expression of these transporters 
has been described, which could also present another barrier and 
contribute to reduced ASD uptake in epileptic tissue (75, 88).
Transport of ASDs by Efflux Transporters
Conclusive evidence that ASDs are transported by efflux trans-
porters at therapeutic concentrations is considered the weak link 
in the transporter hypothesis (101). Early studies suggested that 
several ASDs may be substrates for P-gp and/or MRPs. However, 
researchers from different studies used different models, meth-
odologies, and analytical methods with different sensitivities 
which yielded inconsistent results. Researchers who attempted 
to identify ASDs as substrates of P-gp, MRPs, and/or BCRP 
mainly used three approaches: transporter-overexpressing cell 
lines, transporter inhibition in cell lines and/or in animals, and 
transporter gene knockout mice (82). Each of these approaches 
has its own strengths and weaknesses. For example, transporter-
overexpressing cell lines only allow in vitro analysis. Transporter 
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inhibitors may lack specificity and interact with more than one 
transporter, and knockout mice may show potential compensa-
tory upregulation of other transporters, which may complicate 
the situation (78). Therefore, all three approaches may need to 
be used together in one thorough study to obtain conclusive data 
(78). In addition, compared to chemotherapeutic drugs that are 
usually high-affinity substrates for P-gp and MRPs, ASDs are 
weak substrates for the efflux transporters and more easily cross 
the blood–brain barrier under physiological conditions (12).
ASD Transport by P-gp. P-glycoprotein transports a wide range 
of structurally and functionally diverse compounds, which are 
primarily hydrophobic and amphipathic compounds (81). Most 
ASDs are planar lipophilic molecules, and therefore, theoretically 
many ASDs should be P-gp substrates (11, 80).
The first report of P-gp-mediated transport of an ASD came 
from Tishler et al. (77), who reported lower steady-state intracel-
lular phenytoin concentrations in MDR1-expressing neuroecto-
dermal cells as compared to MDR1-negative cells. P-gp-mediated 
phenytoin transport was also demonstrated in vivo using brain 
microdialysis in normal rats after administration of P-gp inhibi-
tors (79), in rats with SE-induced P-gp upregulation (44), and 
in mdr1a/b knockout mice (102). Phenobarbital, lamotrigine, 
felbamate, and oxcarbazepine were shown to be transported by 
P-gp in rat brain microdialysis studies using verapamil as a P-gp 
inhibitor (103, 104). In contrast, one study using mdr1a knockout 
mice and wild-type control mice showed that out of the seven 
commonly used ASDs (phenobarbital, phenytoin, carbamaz-
epine, vigabatrin, lamotrigine, gabapentin, and topiramate), only 
topiramate appeared to be a P-gp substrate (82). However, remain-
ing mdr1b expression and potential compensatory upregulation 
of other efflux transporters in mdr1a knockout mice could be 
limitations of the study (82).
Previous studies on P-gp-mediated transport of carbamaze pine 
yielded inconsistent results (63). Owen et al. (105) concluded that 
carbamazepine was not a substrate for P-gp based on results from 
experiments with mdr1a/b knockout mice, P-gp-overexpressing 
Caco-2 cells, and flow cytometry in human lymphocytes using 
rhodamine 123. In contrast, two other studies, one using mdr1a/b 
knockout mice and the other using in  vivo microdialysis with 
verapamil, supported that P-gp transports carbamazepine 
(102, 106). Data from another microdialysis study in rat suggest 
that P-gp does not transport levetiracetam (107). Baltes et  al. 
(108) demonstrated that P-gp does also not transport valproic 
acid by using efflux assays with transfected MDCKII (dog kidney) 
cells and LLC-PK1 (pig kidney) cells and rat brain microdialysis 
with the P-gp inhibitors verapamil and tariquidar.
While most of the earlier studies focused on rodent transport-
ers, later and more recent studies used cell lines transfected with 
human MDR1 or MRPs in order to identify potential species 
differences in substrate spectrum or transport efficiency of the 
transporters. Baltes et al. (109) conducted bidirectional transport 
assays in monolayers of MDCKII and LLC-PK1 cells transfected 
with complementary DNA containing either MDR1, MRP2, 
mdr1a, or mdr1b sequences to study the transport of phenytoin, 
levetiracetam, and carbamazepine by human and mouse P-gp. 
The authors concluded that in transfected LLC-PK1 cells, both 
phenytoin and levetiracetam were transported by mouse P-gp 
only, while carbamazepine was not transported by human or 
mouse P-gp (109). Luna-Tortós et  al. (110) pointed out that 
conventional bidirectional transport assays may not be suitable 
to identify ASDs as P-gp substrates due to the highly perme-
able nature of most ASDs. Using a modified transport assay 
(concentration equilibrium transport assay; CETA) which allows 
evaluating active transport separately from passive permeability, 
Luna-Tortós et  al. detected P-gp transport of phenytoin, phe-
nobarbital, lamotrigine, levetiracetam, and topiramate, but not 
carbamazepine in MDR1-transfected LLC-PK1 cells (110, 111). 
Zhang et  al. (101) used both the cell monolayer bidirectional 
assay and CETA in MDR1-transfected MDCKII and LLC-PK1 
cells to test if phenytoin, phenobarbital, or ethosuximide were 
transported by P-gp. Results from the CETA experiments sug-
gested concentration-dependent P-gp transport of phenytoin in 
both MDCKII-MDR1 and LLC-PK1-MDR1 cells and transport 
of phenobarbital only in MDCKII-MDR1 cells. In conventional 
bidirectional transport experiments, however, P-gp-mediated 
phenytoin transport was minimal, indicating that either cell 
monolayer permeability may have been too high to detect any 
differences and/or that CETA has superior sensitivity in studying 
the active transport of highly permeable compounds (101).
Nonetheless, the results from in vitro experiments using cell 
lines transfected with human proteins should be confirmed 
using in vivo approaches such as PET (112). Verbeek et al. (113) 
conducted a PET study in rats and concluded that [11C]phenytoin 
was a weak P-gp substrate, as demonstrated by the increase in the 
brain-to-plasma concentration ratio after P-gp inhibition with 
tariquidar. In contrast, [11C]methylphenobarbital was not shown 
to be transported by P-gp in a similarly designed PET study in 
rats and mice (114). At present, data from studies using resected 
human brain or from clinical trials aimed at identifying if P-gp 
transports ASDs are limited (96). The only clinical evidence 
linking overexpression of blood–brain barrier P-gp to reduced 
ASD brain levels came from a pilot study by Marchi et al. (115). 
These authors demonstrated an inverse correlation between the 
brain–plasma concentration ratio of the major active metabolite 
of oxcarbazepine, 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)
azepine-5-carboxamide (10,11-dihydro-10-hydroxycarbamaze-
pine), and the MDR1 mRNA brain expression levels in resected 
epileptic tissue from patients with refractory epilepsy (115).
Since different models yield different results, both in  vivo 
and in vitro data seem to be needed to identify which ASDs are 
substrates for which transporter. In this regard, by combining 
the available evidence (as of 2012), Zhang et al. (96) suggested 
that lamotrigine, oxcarbazepine, phenobarbital, and phenytoin 
are considered definite P-gp substrates, because P-gp-mediated 
transport of these ASDs has been supported by both in vivo and 
in vitro evidence.
ASD Transport by MRPs. Multidrug resistance-associated pro-
teins transport neutral organic drugs and amphiphilic organic 
anions including drugs conjugated to glutathione, sulfate, glu-
curonate, and phosphate (85, 86). Thus, it is possible that MRPs 
transport a number of ASDs and/or their metabolites and limit 
their access to the brain (32).
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Phenytoin transport by MRP1 and/or MRP2 was shown 
in vivo in normal rats using brain microdialysis with the MRP1/2 
inhibitor probenecid (116), in TR− mutant rats that lack MRP2 
(117), and in rats with seizure-induced MRP1 upregulation (118). 
Carbamazepine and oxcarbazepine were shown to be substrates 
of MRP1 and/or MRP2 in microdialysis in  vivo studies with 
probenecid (104, 106). Valproic acid was the first ASD found to 
be a substrate for MRPs in brain endothelial cells (119), but Baltes 
et al. (108) could not confirm this finding using efflux assays with 
transfected LLC-PK1 and MDCKII cells and rat brain microdi-
alysis with the MRP inhibitors probenecid and MK571. Similarly, 
using brain microdialysis in rats, Potschka et  al. (107) showed 
that levetiracetam was not transported by MRP1/2.
Baltes et  al. (109) conducted bidirectional transport assays 
in monolayers of MRP2-transfected MDCKII kidney cells, and 
none of the ASDs tested (phenytoin, levetiracetam, carbamaz-
epine) was found to be transported by MRP2. Using CETA in 
MDCKII kidney cells transfected with human MRP1, MRP2, or 
MRP5, Luna-Tortós et al. reported that none of the ASDs tested 
(topiramate, valproate, carbamazepine, phenytoin, levetiracetam, 
lamotrigine, and phenobarbital) was transported by any of those 
MRPs (111, 112). In vivo studies may be needed to confirm the 
findings from in vitro experiments, but few clinical studies have 
focused on studying the relationship between ASDs and MRPs.
ASD Transport by BCRP. Substrate specificity of BCRP sig-
nificantly overlaps with that of P-gp (120). However, the role 
of BCRP in ASD resistance is less well studied in comparison 
to P-gp or the MRPs (121). Using BCRP-transfected MDCKII 
cells, Cerveny et al. (122) reported that none of the tested ASDs 
(phenobarbital, phenytoin, ethosuximide, primidone, valproate, 
carbamazepine, clonazepam, and lamotrigine) was transported 
by BCRP. However, Nakanishi et  al. (123) reported that the 
brain-to-plasma concentration ratio values of phenobarbital, 
clobazam, zonisamide, gabapentin, tiagabine, and levetiracetam 
were higher in mdr1a/b/Bcrp triple knockout mice than those in 
mdr1a/b double knockout mice, suggesting the involvement of 
BCRP in the transport of these ASDs. Subsequently, Römermann 
et al. (121) reported BCRP transport of lamotrigine using CETA 
in MDCKII cells transfected with murine Bcrp or human BCRP, 
but did not observe transport of phenytoin, phenobarbital, car-
bamazepine, levetiracetam, topiramate, or valproate. Together, 
current evidence suggests that most ASDs are not transported 
by BCRP, though discrepancies exist between in vitro and in vivo 
findings (121).
In summary, available data support the transporter substrate 
status of some ASDs, but overall the evidence is inconsistent and 
incomprehensive. There is a continued need to systematically 
investigate the transporter substrate status of ASDs using in vivo 
and in  vitro models and eventually to confirm the findings in 
epilepsy patients (96).
Mechanisms of Efflux Transporter Upregulation in Epilepsy
An important question that stems from the transporter hypo-
thesis is whether overexpression of efflux transporters at the 
blood–brain barrier observed in epilepsy is acquired or constitu-
tive. Current evidence suggests that seizures, genetic factors, or 
a combination of both are likely to be the major contributors to 
efflux transporter overexpression at the blood–brain barrier in 
epilepsy (59).
Experimental data mostly from animal studies support that 
P-gp upregulation in epileptic regions of the brain occurs mainly 
as a result of seizure activity (124). Rizzi et  al. (102) reported 
mdr1 mRNA upregulation in brain of mice acutely after kainic 
acid-induced seizures and in rats with self-sustained seizures 
after electrically induced SE. Using a rat TLE model in which 
seizures developed spontaneously after electrically induced SE, 
van Vliet et  al. (84) demonstrated that mdr1a mRNA, mdr1b 
mRNA, and P-gp protein levels increased within 1 week after SE. 
Specifically, chronic epileptic rats had persistent overexpression 
of mdr1b mRNA and P-gp protein in endothelial and glial-like 
cells of the ventral temporal lobe, with higher P-gp levels in rats 
that had more seizure activity (84). Levels of mdr1a mRNA and 
P-gp protein levels also increased in whole tissue samples of the 
temporal hippocampus and the parahippocampal cortex that 
are involved in epileptogenesis (44). In another study, Bankstahl 
and Löscher showed overexpression of P-gp protein in brain 
capillary endothelial cells 48  h after SE in two rat models, the 
lithium/pilocarpine model and the basolateral amygdala electri-
cal stimulation model (125). van Vliet et al. (126) also reported 
increased MRP1, MRP2, and BCRP protein expression levels in 
rat astrocytes and cerebral blood vessels after acute SE and in 
chronic epilepsy. Similar to the finding with P-gp, overexpression 
of these transporters was greater in chronic epileptic rats that 
demonstrated progression of epilepsy (126). Recent research in 
the field has postulated two main mechanisms leading to efflux 
transporter overexpression in the brain in epilepsy: (1) ASD-
mediated induction of efflux transporters via nuclear receptors 
and (2) seizure-induced signaling causing efflux transporter 
overexpression.
With regard to the first mechanism, studies on whether ASDs 
induce efflux transporter overexpression have yielded inconsistent 
results. Rizzi et al. (102) reported that twice daily intraperitoneal 
administration of 30 mg/kg phenytoin or 15 mg/kg carbamaz-
epine for 7 days did not alter mdr1 mRNA expression levels in the 
mouse hippocampus. However, P-gp expression levels are highest 
in brain capillaries, and thus, such increases would be masked by 
using total brain samples due to dilution (brain capillaries make 
up only 1% of brain volume) (127). Seegers et  al. (128) found 
that giving rats 30 mg/kg phenobarbital or 50 mg/kg phenytoin 
(following 75 mg/kg on the first day) intraperitoneally daily for 
11 days did not significantly increase endothelial or parenchymal 
P-gp protein expression levels in various brain regions (frontal 
and parietal cortex, basolateral amygdala, hippocampus, dentate 
gyrus, piriform cortex, substantia nigra pars reticulata, and 
cerebellum).
In contrast, in the Coriaria lactone-induced rat SE model, 
Wang-Tilz et  al. (129) reported that giving orally 125  mg/kg 
carbamazepine or 187.5 mg/kg valproic acid daily increased P-gp 
expression in astrocytes and endothelial cells, particularly in the 
hippocampus, the temporal, frontal, and parietal lobes of the 
brain, whereas giving daily 100 mg/kg topiramate or 125 mg/kg 
lamotrigine orally for 30 days did not affect P-gp expression levels. 
However, studies have shown that seizures induce brain capillary 
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P-gp expression levels (130, 131). If P-gp levels were already 
maximally induced in the study of Wang-Tilz et  al. (129), one 
would not expect to see additional increases in P-gp expression 
levels by ASDs. Consistent with this, Wen et al. (132) reported that 
21-day exposure of naïve rats to phenobarbital, carbamazepine, 
or phenytoin given orally twice daily significantly increased P-gp 
activity and protein expression levels in capillary endothelial cells 
in cerebral cortex and hippocampus. The underlying mechanism 
of this induction was not investigated, but the authors specu-
lated that the observed effect was due to ASD activation of the 
ligand-activated transcription factors pregnane X receptor and/
or constitutive androstane receptor (132). In contrast, Ambroziak 
et al. (133) did not observe any changes on P-gp expression or 
activity levels in the GPNT rat brain endothelial cell line and the 
MDCKII cell line that were exposed to phenobarbital, phenytoin, 
or carbamazepine. In this regard, it is important to note that 
ASD-mediated upregulation of drug efflux transporters at the 
blood–brain barrier and in other tissues does not explain why 
some patients are resistant to the very first ASD they are given. 
While this speaks against the theory that ASDs are the main cause 
for drug resistance due to transporter upregulation, it is possible 
that ASDs are one contributor, among others, to refractory epi-
lepsy. Clearly, further studies are needed to draw firm conclusions 
on the effect of ASDs on P-gp expression and activity levels in the 
brain and their contribution to overall drug resistance in epilepsy.
The second mechanism that has been shown to result in 
increased efflux transporter expression levels is through recur-
ring seizures. In this regard, Lazarowski et al. (134) showed that 
daily administration of 3-mercaptopropionic acid (MP) causes 
daily seizures, which result in a progressive increase of P-gp 
protein expression at the blood–brain barrier. Furthermore, these 
researchers showed that the pharmacokinetics of phenytoin are 
altered in the hippocampus of MP-induced epileptic rats and 
that treatment with the P-gp inhibitor nimodipine restored 
normal hippocampal pharmacokinetics of phenytoin resulting 
in seizure control (135). More recently, the MP-induced seizure 
model in mice has been presented as a new drug-resistant model 
that allows screening of drugs at early stages of preclinical tri-
als. After 23 consecutive MP administrations, 100% of animals 
became resistant to phenytoin and 80% of animals developed 
resistance to phenobarbital. Resistance was strongly associated 
with overexpression of P-gp in the cerebral cortex, hippocampus, 
and striatum. Importantly, resistance to drugs that are not P-gp 
substrates such as carbamazepine, diazepam, or levetiracetam 
was not observed (136). Therefore, this new model could be use-
ful for screening novel ASDs that are P-gp substrates and have 
the potential to control seizures in pharmacoresistant epilepsy.
The molecular signaling mechanism underlying increased 
efflux transporter expression levels in epilepsy has been studied 
by our group and others. In this regard, we recently showed that 
seizure-induced glutamate release triggers a signaling pathway 
that involves the N-methyl-d-aspartate receptor, cyclooxyge-
nase-2, and the prostanoid E1 receptor, resulting in increased 
P-gp protein and activity levels at the blood–brain barrier 
(131, 137–139). In addition, evidence from in vitro and in vivo 
rodent studies suggests that targeting this pathway could con-
trol P-gp expression and activity levels, and thus, help increase 
ASD brain penetration and improve ASD efficacy to control 
seizures in drug-resistant epilepsy (131, 137–139). One study 
of Salvamoser et al. (140) showed that exposing isolated porcine 
brain capillaries and human brain capillaries from ASD-resistant 
patients with FCD to glutamate resulted in reduced BCRP pro-
tein expression levels. This finding is in contrast with data from 
human studies comparing BCRP expression between control 
and epileptic human brain tissue (89, 90, 92, 95), and unpub-
lished data from our lab clearly demonstrate seizure-induced 
upregulation of BCRP protein expression and activity levels in 
brain capillaries from chronic epileptic rats. Considering that 
Salvamoser et  al. neither provided data from dose response 
nor conducted time course experiments, the observed effect 
on BCRP in porcine brain capillaries could also be due to 
glutamate-mediated excitotoxicity. This could also explain the 
authors’ observation in brain capillaries from epileptic human 
brain tissue. In this case, capillaries were isolated from resected 
epileptic brain tissue that has already been exposed to glutamate 
released during seizures, and thus, adding additional glutamate 
ex vivo will most likely have caused excitotoxicity. Thus, the 
authors could have misinterpreted glutamate-mediated excito-
toxicity as BCRP downregulation.
Together, in vivo and in vitro experimental data support P-gp 
upregulation in the epileptic brain as a result of glutamate release 
and the downstream signaling pathway. Nevertheless, signaling 
mechanisms that control P-gp and other efflux transporters at 
the blood–brain barrier have to be first confirmed at the human 
blood–brain barrier prior to translational development of this 
strategy (124).
Polymorphisms of Efflux Transporters and ASD Response
Hoffmeyer et  al. (141) were the first to identify a synonymous 
C3435T SNP in exon 26 of the human ABCB1 (MDR1) gene. In 
this particular study, individuals with the TT genotype had statis-
tically significantly lower intestinal P-gp protein expression and 
activity levels as demonstrated by enhanced intestinal uptake of 
the P-gp substrate digoxin (141). Several other ABCB1 polymor-
phisms have been identified later, including a non-synonymous 
G2677T/A SNP in exon 21 and a synonymous C1236T SNP on 
exon 12, both of which are thought to be in linkage disequilib-
rium with C3435T (142) and account for the majority of the 
ABCB1 haplotypes along with the C3435T SNP (78). Since the 
first description of the association between the C3435T SNP 
and P-gp expression and activity levels, numerous studies have 
been conducted in an attempt to replicate the results or identify 
other relevant polymorphisms (143). However, follow-up stud-
ies provided conflicting results. For example, Siegmund et  al. 
(144) reported that in healthy Caucasian individuals, none of 
the genotypes studied, including C3435T, G2677T/A, and other 
putatively functional SNPs, significantly affected duodenal P-gp 
protein expression levels or P-gp in vivo activity.
Similarly, researchers investigating the association between 
ABCB1 polymorphisms and response to ASD treatment found 
inconsistent results. Siddiqui et al. (11) were the first to investi-
gate ASD resistance in relationship to ABCB1 polymorphisms. 
In a study with 315 epilepsy patients, the authors reported that 
patients with refractory epilepsy had a higher frequency of the 
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CC genotype at the C3435T SNP than the TT genotype. However, 
Tan et al. (145) could not confirm the association between the 
C3435T SNP and ASD response in epilepsy. Sills et  al. (146) 
studied the association between the C3435T SNP and pharma-
coresistance in 400 epilepsy patients and found no significant dif-
ferences in allele or genotype frequency between ASD responders 
and non-responders. Tate et al. (60) reported a lack of association 
between the C3435T SNP with phenytoin or carbamazepine 
dosing. Similarly, a study investigating the association between 
the C3435T polymorphism and drug resistance in 171 Korean 
patients with epilepsy yielded a negative result (147). Shahwan 
et al. (148) studied 440 Irish patients with epilepsy and they also 
could not detect significant associations between ASD resistance 
and C3435T or seven other functional variants in the ABCB1 
gene.
Using a gene-wide approach, Kwan et al. (142) genotyped 12 
tagging and candidate SNPs of ABCB1 in 464 Chinese patients 
with epilepsy and revealed significant associations between 
drug resistance and the intronic polymorphism rs3789243, the 
coding polymorphism G2677T/A, and haplotypes containing 
two polymorphisms. In contrast, Leschziner et  al. (149) found 
no significant association between multidrug resistance and 
C3435T, G2677T/A, C1236T, or a set of tagging SNPs that des-
cribe common variations in ABCB1 in a case–control study with 
149 Caucasian epilepsy patients.
Such discrepancies in study results could imply that there is 
no true association between the ABCB1 C3435T polymorphism 
with ASD resistance in epilepsy. An alternative explanation 
could be that the association was masked by confounding 
factors such as heterogeneity in the types of ASDs used in the 
studies, because not all ASDs are P-gp substrates or transported 
to the same extent (8, 148). Differences in seizure types and 
definitions of ASD resistance also add to the overall complexity 
(143, 148). Nevertheless, results from some recent meta-analyses 
demonstrate that negative findings persist even after controlling 
for some of the confounding factors. In this regard, Bournissen 
et al. (150) conducted a meta-analysis of 11 case–control studies 
(total of 3,371 patients) and investigated the relationship between 
ABCB1 C3435T polymorphisms and ASD response. The authors 
did not find a significant association between the ABCB1 C3435T 
SNP and ASD response (odds ratio 1.15; 95% confidence interval 
0.78–1.70; p = 0.48). Stratification of studies by the ethnicity of 
the subjects yielded similar results. A meta-analysis conducted 
by Haerian et al. (151) included 22 genetic association studies 
(total of 6,755 patients) and also did not identify a significant 
association between ABCB1 C3435T polymorphisms and ASD 
response (odds ratio 1.06, 95% confidence interval 0.98–1.14, 
p = 0.12). Stratified subgroup meta-analyses based on the new 
definition of drug-resistant epilepsy proposed by the ILAE and 
based on ethnicity did not reveal any significant associations 
either (151). Thus, Haerian et al. (152) conducted another meta-
analysis to evaluate the association between the ABCB1 C1236T, 
G2677T/A, and C3435T loci and ASD response. A total of 26 
publications (n =  7,831 patients in total) were included for a 
haplotype meta-analysis, which did not reveal any significant 
correlation of the polymorphisms and their haplotypes with 
ASD response either in the general population or in individual 
ethnic groups. Nevertheless, the authors pointed out that the 
available data did not allow subgroup analyses based on other 
confounders, such as types of ASDs used or types of epilepsy 
(152). Thus, an association between ABCB1 polymorphisms and 
P-gp expression and activity levels in patients with refractory 
epilepsy needs to be confirmed in brain tissue first before the role 
of ABCB1 polymorphisms in ASD resistance can be accepted 
(153). If there was conclusive evidence for C3435T genotype-
dependent P-gp expression at the blood–brain barrier, a lack of 
association between ABCB1 polymorphisms and ASD response 
could potentially negate the role P-gp plays in refractory epilepsy 
(146). Nevertheless, at present there is inadequate evidence 
supporting the relationship between ABCB1 polymorphisms 
and brain ABCB1 mRNA or P-gp protein expression levels in 
refractory epilepsy (92, 142, 153).
Even less studied is the role of how ABCC2 polymorphisms 
could affect pharmacoresistance in epilepsy, and studies pub-
lished so far have yielded inconsistent results. In two recently 
published meta-analysis studies, the researchers investigated the 
relationship between three common ABCC2 SNPs (c.-24C>T, 
c.1249G>A, and c.3972C>T) and ASD response and found a 
significant association between ASD resistance and c.-24C>T, 
but not with the other two SNPs (154, 155). However, authors of 
both reports noted some limitations to their findings, including 
ethnicity differences in the identified association and variability 
in how ASD resistance was defined among the studies (154, 155). 
In contrast, two other meta-analyses identified a significant 
association between ABCC2 c.1249G>A and pharmacoresistance 
(156, 157). The discrepancy in results could be explained by the 
heterogeneity in the enrolled studies, and thus, current findings 
need to be confirmed with larger well-designed studies (155).
Overcoming Pharmacoresistance with Transporter Inhibitors
One potential strategy to overcome ASD resistance is by directly 
inhibiting the efflux transporters assumed to be in part respon-
sible for this phenomenon. For P-gp, there are four generations 
of inhibitors (158). First-generation inhibitors are non-specific 
for P-gp, such as cyclosporine A and verapamil (2). Second-
generation inhibitors [e.g., PSC833 (valspodar), a cyclosporine 
A analog] are more specific for P-gp, but they still interfere with 
cytochrome CYP3A4 metabolizing enzyme (2). Third-generation 
P-gp inhibitors are P-gp-specific and do not interfere with drug 
metabolizing enzymes (2, 158). Tariquidar (XR9576) in particular 
is a non-competitive P-gp inhibitor with greater affinity for P-gp 
than its substrates (20). Finally, fourth-generation P-gp inhibi-
tors (e.g., the cyclic peptide QZ59SE and the natural compounds 
lamellarin and gomisin A) display low toxicity but high selectivity 
and potency are currently under development and evaluated for 
their use in humans (158, 159). MRP inhibitors include probene-
cid, MK-571, and LY402913 (2). Probenecid effectively inhibits 
MRPs, especially MRP1 and MRP2 (116).
Experimental data support the concomitant use of P-gp/MRP 
inhibitors with ASDs as a strategy to increase anticonvulsant brain 
uptake and efficacy and overcome pharmacoresistance in animal 
models. Clinckers et al. (104) demonstrated in an in vivo micro-
dialysis study that inhibition of P-gp/MRPs using verapamil/
probenecid counteracted pharmacoresistance to oxcarbazepine 
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in rats that had experienced pilocarpine-induced seizures. Brandt 
et al. (47) conducted a study with TLE rats that were divided into 
two groups based on their response/non-response to phenobar-
bital at the maximum tolerated doses and found that tariquidar 
completely counteracted pharmacoresistance. In a similar study, 
van Vliet et al. (48) first demonstrated that therapeutic doses of 
phenytoin only partially controlled seizures in chronic epileptic 
rats where P-gp levels were upregulated in the ventral hippocam-
pus and entorhinal cortex, which was determined by Western 
blotting of the homogenized brain areas. When coadministered 
with tariquidar, phenytoin brain concentrations significantly 
increased and seizures were almost completely controlled (48).
Verapamil, nifedipine, and diltiazem have also been coadmin-
istered with ASDs to inhibit P-gp and been evaluated for their 
effect in increasing ASD brain levels and consequently reducing 
seizures in patients in clinical practice. Because calcium channel 
blockers can have intrinsic anticonvulsant activity and inhibi-
tory effect on CYP3A4, it could be difficult to differentiate the 
effect on P-gp inhibition (2, 160). Several case reports show that 
adding verapamil to an ASD regimen improved seizure control 
(160–162). One pilot non-placebo-controlled open-label study 
in 19 adult patients with refractory TLE found that adding 
verapamil (120  mg daily in 13 patients and 240  mg daily in 6 
patients) to the existing ASD treatment improved seizure control 
in a dose-dependent manner; in seven patients seizure frequency 
was reduced by at least 50% (163). In the first randomized, 
double-blinded placebo-controlled trial that was conducted to 
evaluate the safety and efficacy of once daily 240 mg verapamil as 
an add-on therapy in refractory epilepsy patients with focal onset 
seizures, no statistically significant decrease in seizure frequency 
was observed in the 12 patients who finished the study; none of 
the patients achieved 50% or more seizure reduction (164). In this 
study, adverse effects unique to the verapamil group included skin 
rashes and feet edema, while no cardiovascular adverse effects 
were reported. A more recent non-placebo-controlled open-label 
study explored the efficacy of low-dose verapamil (20 mg three 
times daily) as adjunctive treatment in refractory epilepsy (165). 
The authors reported that 10 out of 19 patients who remained 
in the study achieved 50% or more seizure reduction, and none 
of the patients experienced cardiovascular or hemodynamic 
adverse events (165).
Together, the major limitations of these clinical studies are 
their small patient group size and the use of relatively unspecific 
P-gp inhibitors (e.g., verapamil), and thus, no firm conclusion 
about the efficacy of add-on P-gp inhibitors in refractory epilepsy 
can be drawn at present. This is especially true given the discrep-
ancy in findings from open-label and double-blinded studies.
Summary
Sisodiya (6) proposed that a mechanism causing refractory 
epilepsy needs to be involved in ASD resistance with appropriate 
functionality and presence in the epileptogenic brain region, and 
counteracting such a mechanism should reduce refractoriness. 
In the rodent model, overexpression of P-gp has been observed 
in epileptic brain tissue, and such overexpression correlates 
with reduced brain ASD concentrations. Indeed, ASD-resistant 
rats have higher brain P-gp protein expression levels than 
ASD-responsive rats, and P-gp inhibition with a specific inhibi-
tor, such as tariquidar, counteracts ASD resistance (59, 166). 
However, whether such findings from rodent studies can be 
extrapolated to refractory epilepsy in human patients is unclear 
(59, 166). It is also unclear if seizure-induced P-gp upregulation 
at the blood–brain barrier has clinically relevant effects on ASD 
brain delivery and ultimately on ASD efficacy in epilepsy patients, 
or if P-gp upregulation is no more than an epiphenomenon of 
uncontrolled seizures (45).
In vitro evidence shows that most ASDs are weak substrates of 
human P-gp at best (167), but it has also been argued that signifi-
cant overexpression of multidrug transporters may still restrict 
ASD access to epileptic neurons in vivo (45). On the other hand, 
as revealed by several meta-analyses, the transporter hypothesis 
is not supported by genetic association studies (167). Clinical 
evidence supporting efflux transporter-mediated ASD transport 
in the human brain has not been demonstrated yet (166). Recent 
studies utilizing PET/MR imaging, however, demonstrate for 
the first time increased P-gp transport activity in patients with 
drug-resistant epilepsy and that seizure reduction after surgery 
leads to a decrease in P-gp overactivity (100, 168). Together, 
these patient data suggest that an optimal outcome after surgery 
is associated with a reduction in P-gp transport activity and that 
P-gp overexpression could serve as a surrogate marker for drug-
resistant epilepsy.
In order to fully assess if P-gp upregulation has any relevant 
consequences on pharmacoresistance, studying P-gp expression 
in brain tissue from both ASD-responsive and ASD-resistant 
patients and/or conducting PET imaging using P-gp substrates 
or inhibitors in patients would be critical (45, 166). At present, 
aspects of the transporter hypothesis are still controversial, and 
further research is needed to determine the clinical relevance of 
efflux transporter overexpression at the blood–brain barrier.
CONCLUSiON
Despite the introduction of newer generations of ASDs, phar-
macoresistance remains one of the biggest challenges in epilepsy 
treatment. In this review article, we summarize various theories 
that have been proposed to explain the mechanism(s) underly-
ing refractory epilepsy with an emphasis on the transporter 
hypothesis.
The pharmacokinetic hypothesis is supported by case reports 
that describe subtherapeutic ASD plasma levels in refractory 
patients, but additional substantiating evidence from animal or 
human studies is lacking. The neural network hypothesis was 
inspired by molecular evidence showing the existence of signaling 
molecules that guide the abnormal growth of axons in epilepsy, 
but this hypothesis is limited by its inability to account for the 
occurrence of pharmacoresistance in some but not all epilepsy 
patients. The intrinsic severity hypothesis is supported by the 
clinical finding that high frequency of pretreatment seizures is 
associated with refractoriness, but it fails to explain the complex 
temporal patterns of ASD resistance in some patients, and a 
mechanistic explanation behind this hypothesis is also lacking. 
The gene variant hypothesis is supported by some identified asso-
ciations between gene variations and ASD resistance, but study 
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findings are often inconsistent and need to be confirmed in larger 
populations. The strongest evidence for the target hypothesis 
exists for the loss of use-dependent sodium channel blockade by 
carbamazepine, but beyond this observation its general utility is 
limited. Finally, as the most cited hypothesis of refractory epilepsy, 
the transporter hypothesis is strongly supported by evidence of 
efflux transporter overexpression at the blood–brain-barrier, but 
other aspects of the hypothesis remain controversial, especially 
the clinical relevance of efflux transporter overexpression and the 
transporter substrate status of many ASDs.
It is clear from current evidence that pharmacoresistance in 
epilepsy is a multifactorial phenomenon, but based on existing 
evidence more work is needed to reinforce and integrate the cur-
rent theories with the ultimate goal of guiding the development 
of better epilepsy therapies.
FUTURe PeRSPeCTiveS
Current Status and Future Development  
of Treatment Guidelines
The American Academy of Neurology and the American Epilepsy 
Society guidelines on the treatment of refractory epilepsy were 
last updated in 2004. These guidelines conclude that all newer 
ASDs evaluated (gabapentin, lamotrigine, topiramate, tiagabine, 
oxcarbazepine, levetiracetam, and zonisamide) are appropriate 
for adjunctive therapy in refractory partial epilepsy in adults (7). 
However, such recommendations were made in the absence of 
head-to-head clinical trials that were rationally designed to evalu-
ate the efficacy of two or more ASDs at comparable doses (7). Two 
other sets of guidelines by the American Academy of Neurology 
published in 2003 and 2013, respectively, conclude that anterome-
sial temporal lobe resection in patients with disabling complex 
partial seizures is more beneficial than continuing pharmaco-
therapy, and that vagus nerve stimulation is possibly useful for 
treating children with epilepsy and patients with Lennox–Gastaut 
syndrome (169, 170). These treatment guidelines recognize the 
limitations of current treatment options and the scarcity of 
quality evidence for treating refractory epilepsy. Nevertheless, in 
addition to incorporating recent clinical evidence, future treat-
ment guidelines need to place more emphasis on personalizing 
the therapy of patients with refractory epilepsy. In this regard, 
factors specific to individual patients such as disease etiology, 
medical history, drug response, temporal patterns of refractori-
ness, as well as the multifactorial nature of pharmacoresistance 
need to be taken into account to improve therapy of patients with 
refractory epilepsy.
Further Development of Current 
Hypotheses
Each of the current hypotheses has its limitations, and although 
each individual theory is applicable to a subgroup of patients, 
some of these mechanisms may overlap in patients (59). Spe-
cifically, it has been proposed that the target hypothesis and the 
transporter hypothesis are not mutually exclusive and that one 
mechanism could be predominant for some ASDs but not for 
others. For example, Remy and Beck (63) proposed that the target 
mechanism plays a major role in resistance to carbamazepine, as 
there is conflicting evidence on its P-gp substrate status.
Although the majority of the literature focuses on the trans-
porter hypothesis, further evidence on the clinical relevance of 
efflux transporter overexpression in refractory epilepsy is still 
needed. PET studies using P-gp ligands can be used to investi-
gate how P-gp expression and activity is changed in epilepsy and 
potentially be used to identify patients who can benefit from the 
use of P-gp inhibitors in the future (17). Until more data become 
available, it is fair to say that transporter overexpression is most 
likely not the only factor that plays in ASD resistance and that 
the best evidence available only supports the plausibility for the 
clinical role of efflux transporters in refractory epilepsy.
Treatment Strategies
Based on the transporter hypothesis, one strategy to counteract 
pharmacoresistance in epilepsy is the adjunctive use of P-gp 
inhibitors (59). However, the use of P-gp-specific inhibitors is not 
without concerns as systemic inhibition of P-gp could increase 
plasma concentrations of drugs and toxins, potentially leading to 
systemic toxicity (20, 44). The use of a non-specific P-gp inhibitor, 
such as verapamil, can be limited by its effect on heart rate and 
blood pressure (160). Though one small open-label study showed 
that low-dose verapamil was well tolerated (165), this finding still 
needs to be confirmed in larger double-blinded studies. Another 
approach we and others suggested is modulating transporter reg-
ulation in epilepsy without affecting basal transporter expression 
and function (131, 137–139). Other strategies include developing 
new ASDs that are not substrates of efflux transporters (102) and 
bypassing these transporters using targeted delivery systems (12). 
Intranasal administration of ASDs has been proposed, but more 
pharmacokinetic evidence on whether intranasal administration 
enhances brain delivery of drugs is needed. Intracerebral admin-
istration is another option, but the invasive nature of the method 
limits its application (124).
One important approach to improve the prognosis of epi-
lepsy is to develop new ASDs with greater efficacy, such as by 
targeting mechanisms unaffected by current ASDs (14, 171). 
Consequently, there is a need to enhance the understanding of 
the neurobiological mechanisms underlying ASD resistance in 
patients and to identify and test novel treatments using various 
models, including animal models of refractory epilepsy (14, 17). 
In addition, efforts should be made to search for drugs able to 
interfere with the progression of epilepsy or hinder neurodegen-
eration (17).
Several non-pharmacological strategies are currently under 
development. Stem cell-based therapies and gene therapy are 
promising strategies, but they have not been tested in clinical tri-
als for epilepsy (172, 173). Potential mechanisms of gene therapy 
include inhibiting neuronal hyperexcitability, promoting neu-
ronal survival, and facilitating circuit repair by transduction of 
endogenous cells and expression of modulators or neurotrophic 
factors. Stem cell-based therapies can be used to replace damaged 
or dead neurons, provide trophic support to facilitate neuronal 
survival and repair, or act as a platform for ex vivo gene therapy 
where transplanted neurons are genetically modified to produce 
therapeutic substances (172).
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Drug resistance is one of the most serious problems in epile-
psy treatment, and much effort has been made to elucidate the 
underlying multifactorial mechanisms. In the near future, as we 
gain more evidence on the proposed hypotheses, we may antici-
pate further application of treatment strategies that are developed 
from current understanding of drug resistance, as well as other 
pharmacological and non-pharmacological approaches that aim 
to inhibit epileptogenesis and neuro degeneration.
AUTHOR CONTRiBUTiONS
FT drafted the outline, wrote the first draft of the manuscript, and 
revised the manuscript. AH drafted the figures, wrote parts of the 
manuscript, and revised the figures and manuscript. BB drafted 
the outline, wrote parts of the manuscript, and revised the figures 
and manuscript.
ACKNOwLeDGMeNTS
We thank and acknowledge our team members Stephanie Ede-
lmann and Nader El Seblani for editorial assistance, and we thank 
and acknowledge Tom Dolan at UK Information Technology 
Services for graphical assistance. The content is solely the res-
ponsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health.
FUNDiNG
The project described was supported by grant number 1 
R01NS079507 from the National Institute of Neurological Dis-
orders and Stroke (to BB). The content is solely the responsibility 
of the authors and does not necessarily represent the official views 
of the National Institute of Neurological Disorders and Stroke or 
the National Institutes of Health.
ReFeReNCeS
1. Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, 
Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. 
Neurology (2011) 77:1005–12. doi:10.1212/WNL.0b013e31822cfc90 
2. Loscher W, Potschka H. Role of multidrug transporters in pharma-
coresistance to antiepileptic drugs. J Pharmacol Exp Ther (2002) 301:7–14. 
doi:10.1124/jpet.301.1.7 
3. Mohanraj R, Brodie MJ. Early predictors of outcome in newly diagnosed 
epilepsy. Seizure (2013) 22:333–44. doi:10.1016/j.seizure.2013.02.002 
4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 
(2000) 342:314–9. doi:10.1056/NEJM200002033420503 
5. French JA. Refractory epilepsy: one size does not fit all. Epilepsy Curr (2006) 
6:177–80. doi:10.1111/j.1535-7511.2006.00137.x 
6. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 
(2003) 16:197–201. doi:10.1097/00019052-200304000-00013 
7. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, 
et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of 
refractory epilepsy: report of the Therapeutics and Technology Assessment 
Subcommittee and Quality Standards Subcommittee of the American 
Academy of Neurology and the American Epilepsy Society. Neurology (2004) 
62:1261–73. doi:10.1212/01.WNL.0000123695.22623.32
8. Soranzo N, Goldstein DB, Sisodiya SM. The role of common variation in drug 
transporter genes in refractory epilepsy. Expert Opin Pharmacother (2005) 
6:1305–12. doi:10.1517/14656566.6.8.1305 
9. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect 
of past treatment history. Neurology (2008) 70:54–65. doi:10.1212/01.wnl. 
0000286959.22040.6e 
10. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, 
et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc 
task force of the ILAE Commission on therapeutic strategies. Epilepsia (2010) 
51:1069–77. doi:10.1111/j.1528-1167.2009.02397.x 
11. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. 
Association of multidrug resistance in epilepsy with a polymorphism in the 
drug-transporter gene ABCB1. N Engl J Med (2003) 348:1442–8. doi:10.1056/
NEJMoa021986 
12. Loscher W, Potschka H. Drug resistance in brain diseases and the role of 
drug efflux transporters. Nat Rev Neurosci (2005) 6:591–602. doi:10.1038/
nrn1728 
13. French JA. Refractory epilepsy: clinical overview. Epilepsia (2007) 48 
(Suppl 1):3–7. doi:10.1111/j.1528-1167.2007.00992.x 
14. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and 
developmental agents. CNS Drugs (2011) 25:89–107. doi:10.2165/11584860- 
000000000-00000 
15. Schmidt D, Sillanpaa M. Evidence-based review on the natural history of 
the epilepsies. Curr Opin Neurol (2012) 25:159–63. doi:10.1097/WCO. 
0b013e3283507e73 
16. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern 
antiepileptic drugs for refractory epilepsy: systematic review and meta- 
analysis. Epilepsia (2010) 51:7–26. doi:10.1111/j.1528-1167.2009.02299.x 
17. Loscher W, Schmidt D. Modern antiepileptic drug development has failed 
to deliver: ways out of the current dilemma. Epilepsia (2011) 52:657–78. 
doi:10.1111/j.1528-1167.2011.03024.x 
18. Sisodiya S. Etiology and management of refractory epilepsies. Nat Clin Pract 
Neurol (2007) 3:320–30. doi:10.1038/ncpneuro0521 
19. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treat-
ment response in newly diagnosed epilepsy. Neurology (2012) 78:1548–54. 
doi:10.1212/WNL.0b013e3182563b19 
20. Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert 
Rev Neurother (2006) 6:397–406. doi:10.1586/14737175.6.3.397 
21. Perry MS, Duchowny M. Surgical versus medical treatment for refractory 
epilepsy: outcomes beyond seizure control. Epilepsia (2013) 54:2060–70. 
doi:10.1111/epi.12427 
22. Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, et  al.  
The consequences of refractory epilepsy and its treatment. Epilepsy Behav 
(2014) 37:59–70. doi:10.1016/j.yebeh.2014.05.031 
23. Felton EA, Cervenka MC. Dietary therapy is the best option for refractory 
nonsurgical epilepsy. Epilepsia (2015) 56:1325–9. doi:10.1111/epi.13075 
24. Vaccarezza MM, Silva WH. Dietary therapy is not the best option for refrac-
tory nonsurgical epilepsy. Epilepsia (2015) 56:1330–4. doi:10.1111/epi.13074 
25. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but 
preventable condition? Seizure (2002) 11:77–84. doi:10.1053/seiz.2002.0593 
26. Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, 
Allen Hauser W, et  al. Remission and relapse in a drug-resistant epilepsy 
population followed prospectively. Epilepsia (2011) 52:619–26. doi:10.1111/ 
j.1528-1167.2010.02929.x 
27. Neligan A, Bell GS, Elsayed M, Sander JW, Shorvon SD. Treatment changes 
in a cohort of people with apparently drug-resistant epilepsy: an extended 
follow-up. J Neurol Neurosurg Psychiatry (2012) 83:810–3. doi:10.1136/jnnp- 
2011-302085 
28. Neligan A, Bell GS, Sander JW, Shorvon SD. How refractory is refractory 
epilepsy? Patterns of relapse and remission in people with refractory 
epilepsy. Epilepsy Res (2011) 96:225–30. doi:10.1016/j.eplepsyres.2011. 
06.004 
29. Briggs DE, French JA. What makes epilepsy drug refractory? Expert Rev 
Neurother (2003) 3:127–31. doi:10.1586/14737175.3.1.127 
30. Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antie-
pileptic drug refractoriness. Epilepsy Curr (2008) 8:127–30. doi:10.1111/ 
j.1535-7511.2008.00272.x 
31. Beleza P. Refractory epilepsy: a clinically oriented review. Eur Neurol (2009) 
62:65–71. doi:10.1159/000222775 
32. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance 
in epilepsy: expression of drug resistance proteins in common causes of 
refractory epilepsy. Brain (2002) 125:22–31. doi:10.1093/brain/awf002 
16
Tang et al. Drug Resistance in Epilepsy
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 301
33. Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. 
Eur J Paediatr Neurol (2006) 10:57–65. doi:10.1016/j.ejpn.2005.11.009 
34. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D’Giano C. 
ABC transporters during epilepsy and mechanisms underlying multi-
drug resistance in refractory epilepsy. Epilepsia (2007) 48(Suppl 5):140–9. 
doi:10.1111/j.1528-1167.2007.01302.x 
35. Lazarowski A, Massaro M, Schteinschnaider A, Intruvini S, Sevlever G, 
Rabinowicz A. Neuronal MDR-1 gene expression and persistent low levels 
of anticonvulsants in a child with refractory epilepsy. Ther Drug Monit 
(2004) 26:44–6. doi:10.1097/00007691-200402000-00010 
36. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. Tuberous 
sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. 
Pediatr Neurol (1999) 21:731–4. doi:10.1016/S0887-8994(99)00074-0 
37. Vazquez SE, D’Giano C, Carpintiero S, Coronel K, Ugarnes G, Lazarowski A. 
Increase 99mTc-SESTAMIBI (MIBI) liver clearance could identified epileptic 
pharmacoresistant patients. A preliminary study. Epilepsia (2004) 45:120. 
38. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Okuda M. Clinical evalua-
tion of plasma free phenytoin measurement and factors influencing its 
protein binding. Biopharm Drug Dispos (2006) 27:77–84. doi:10.1002/ 
bdd.486 
39. Paul F, Veauthier C, Fritz G, Lehmann TN, Aktas O, Zipp F, et al. Perioperative 
fluctuations of lamotrigine serum levels in patients undergoing epilepsy 
surgery. Seizure (2007) 16:479–84. doi:10.1016/j.seizure.2007.03.006 
40. Dalaklioglu S. Evaluating appropriateness of digoxin, carbamazepine, val-
proic acid, and phenytoin usage by therapeutic drug monitoring. Clin Lab 
(2013) 59:325–31. doi:10.7754/Clin.Lab.2012.120425 
41. Fagiolino P, Vazquez M, Maldonado C, Ruiz ME, Volonte MG, Orozco-
Suarez S, et al. Usefulness of salivary drug monitoring for detecting efflux 
transporter overexpression. Curr Pharm Des (2013) 19:6701–8. doi:10.2174/ 
13816128113199990368 
42. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, 
Szekeres T, et  al. The predictive value of MDR1, CYP2C9, and CYP2C19 
polymorphisms for phenytoin plasma levels. Pharmacogenomics J (2001) 
1:204–10. doi:10.1038/sj.tpj.6500025 
43. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. 
Intestinal expression of cytochrome P450 enzymes and ABC transporters 
and carbamazepine and phenytoin disposition. Acta Neurol Scand (2007) 
115:232–42. doi:10.1111/j.1600-0404.2006.00761.x 
44. van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, 
Aronica E, et  al. Region-specific overexpression of P-glycoprotein at the 
blood-brain barrier affects brain uptake of phenytoin in epileptic rats. 
J Pharmacol Exp Ther (2007) 322:141–7. doi:10.1124/jpet.107.121178 
45. Loscher W, Luna-Tortós C, Römermann K, Fedrowitz M. Do ATP-binding 
cassette transporters cause pharmacoresistance in epilepsy? Problems and 
approaches in determining which antiepileptic drugs are affected. Curr 
Pharm Des (2011) 17:2808–28. doi:10.2174/138161211797440212 
46. Volk HA, Löscher W. Multidrug resistance in epilepsy: rats with drug-resistant 
seizures exhibit enhanced brain expression of P-glycoprotein compared with 
rats with drug-responsive seizures. Brain (2005) 128:1358–68. doi:10.1093/
brain/awh437 
47. Brandt C, Bethmann K, Gastens AM, Loscher W. The multidrug transporter 
hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model 
of temporal lobe epilepsy. Neurobiol Dis (2006) 24:202–11. doi:10.1016/j.
nbd.2006.06.014 
48. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, 
Wadman WJ, et al. Inhibition of the multidrug transporter P-glycoprotein 
improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 
(2006) 47:672–80. doi:10.1111/j.1528-1167.2006.00496.x 
49. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, 
and carbamazepine: individual variation in relation to seizure frequency and 
type. Neurology (1984) 34:1252–5. doi:10.1212/WNL.34.9.1252 
50. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, 
et  al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther 
Drug Monit (2003) 25:347–63. doi:10.1097/00007691-200306000-00016 
51. Fang M, Xi ZQ, Wu Y, Wang XF. A new hypothesis of drug refractory epilepsy: 
neural network hypothesis. Med Hypotheses (2011) 76:871–6. doi:10.1016/j.
mehy.2011.02.039 
52. Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to 
antiepileptic drugs. Epilepsia (2013) 54(Suppl 2):33–40. doi:10.1111/epi.12182 
53. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. 
Early development of intractable epilepsy in children: a prospective study. 
Neurology (2001) 56:1445–52. doi:10.1212/WNL.56.11.1445 
54. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of 
pharmacoresistant epilepsy. Epilepsy Res (2007) 75:192–6. doi:10.1016/j.
eplepsyres.2007.06.003 
55. Brodie MJ. Road to refractory epilepsy: the Glasgow story. Epilepsia (2013) 
54(Suppl 2):5–8. doi:10.1111/epi.12175 
56. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic 
seizure does not improve the prognosis of epilepsy. First Seizure 
Trial Group (FIRST Group). Neurology (1997) 49:991–8. doi:10.1212/
WNL.49.4.991 
57. Camfield C, Camfield P, Gordon K, Dooley J. Does the number of seizures 
before treatment influence ease of control or remission of childhood epi-
lepsy? Not if the number is 10 or less. Neurology (1996) 46:41–4. doi:10.1212/
WNL.46.1.41 
58. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D, et  al. 
Immediate versus deferred antiepileptic drug treatment for early epilepsy and 
single seizures: a randomised controlled trial. Lancet (2005) 365:2007–13. 
doi:10.1016/S0140-6736(05)66694-9 
59. Schmidt D, Loscher W. New developments in antiepileptic drug resistance: 
an integrative view. Epilepsy Curr (2009) 9:47–52. doi:10.1111/j.1535-7511. 
2008.01289.x 
60. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. 
Genetic predictors of the maximum doses patients receive during clinical use 
of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci 
U S A (2005) 102:5507–12. doi:10.1073/pnas.0407346102 
61. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic 
polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. 
Pharmacogenetics (2001) 11:287–91. doi:10.1097/00008571-200106000-00002 
62. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, et  al.  
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 
-24C>T polymorphism in young and adult patients with epilepsy. Pharma-
cogenet Genomics (2009) 19:353–62. doi:10.1097/FPC.0b013e328329940b 
63. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance 
in epilepsy. Brain (2006) 129:18–35. doi:10.1093/brain/awh682 
64. Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, et al. Multidrug resis-
tance in epilepsy and polymorphisms in the voltage-gated sodium channel 
genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, geno-
type, and mRNA expression. Pharmacogenet Genomics (2008) 18:989–98. 
doi:10.1097/FPC.0b013e3283117d67 
65. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, et  al.  
A common polymorphism in the SCN1A gene associates with phenytoin 
serum levels at maintenance dose. Pharmacogenet Genomics (2006) 16:721–6. 
doi:10.1097/01.fpc.0000230114.41828.73 
66. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Associa tion 
between SCN1A polymorphism and carbamazepine-resistant epilepsy. 
Br J Clin Pharmacol (2008) 66:304–7. doi:10.1111/j.1365-2125.2008.03203.x 
67. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differ en tial 
role of sodium channels SCN1A and SCN2A gene polymorphisms with 
epilepsy and multiple drug resistance in the North Indian population. 
Br J Clin Pharmacol (2009) 68:214–20. doi:10.1111/j.1365-2125.2009. 
03437.x 
68. Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK, Mittal B. Pharmacogenomic 
association study on the role of drug metabolizing, drug transporters 
and drug target gene polymorphisms in drug-resistant epilepsy in a 
north Indian population. Indian J Hum Genet (2011) 17(Suppl 1):S32–40. 
doi:10.4103/0971-6866.80357 
69. Abo El Fotoh WM, Abd El Naby SA, Habib MS, ALrefai AA, Kasemy ZA. 
The potential implication of SCN1A and CYP3A5 genetic variants on antie-
pileptic drug resistance among Egyptian epileptic children. Seizure (2016) 
41:75–80. doi:10.1016/j.seizure.2016.07.005 
70. Grover S, Gupta M, Kukreti R. Challenges and recommendations for 
conducting epidemiological studies in the field of epilepsy pharmaco-
genetics. Indian J Hum Genet (2011) 17(Suppl 1):S4–11. doi:10.4103/ 
0971-6866.80351 
71. Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et  al.  
A novel mechanism underlying drug resistance in chronic epilepsy. Ann 
Neurol (2003) 53:469–79. doi:10.1002/ana.10473 
17
Tang et al. Drug Resistance in Epilepsy
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 301
72. Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr 
Opin Neurol (2006) 19:175–80. doi:10.1097/01.wco.0000218235.67840.82 
73. Loup F, Wieser HG, Yonekawa Y, Aguzzi A, Fritschy JM. Selective alterations 
in GABAA receptor subtypes in human temporal lobe epilepsy. J Neurosci 
(2000) 20:5401–19. 
74. Pirker S, Schwarzer C, Czech T, Baumgartner C, Pockberger H, Maier H, 
et al. Increased expression of GABA(A) receptor beta-subunits in the hip-
pocampus of patients with temporal lobe epilepsy. J Neuropathol Exp Neurol 
(2003) 62:820–34. doi:10.1093/jnen/62.8.820 
75. Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Scheper RJ, 
Harding BN, et  al. Vascular colocalization of P-glycoprotein, multidrug- 
resistance associated protein 1, breast cancer resistance protein and major 
vault protein in human epileptogenic pathologies. Neuropathol Appl Neuro-
biol (2006) 32:51–63. doi:10.1111/j.1365-2990.2005.00699.x 
76. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/
ABCG2) in drug transport – an update. AAPS J (2015) 17:65–82. doi:10.1208/
s12248-014-9668-6 
77. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. 
MDR1 gene expression in brain of patients with medically intractable epi-
lepsy. Epilepsia (1995) 36:1–6. doi:10.1111/j.1528-1157.1995.tb01657.x 
78. Kwan P, Brodie MJ. Potential role of drug transporters in the patho-
genesis of medically intractable epilepsy. Epilepsia (2005) 46:224–35. 
doi:10.1111/j.0013-9580.2005.31904.x 
79. Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated 
transport of phenytoin at the blood-brain barrier of rats. Epilepsia (2001) 
42:1231–40. doi:10.1046/j.1528-1157.2001.01901.x 
80. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, 
Bingaman W, et  al. Overexpression of multiple drug resistance genes in 
endothelial cells from patients with refractory epilepsy. Epilepsia (2001) 
42:1501–6. doi:10.1046/j.1528-1157.2001.12301.x 
81. Chufan EE, Sim HM, Ambudkar SV. Molecular basis of the polyspecificity 
of P-glycoprotein (ABCB1): recent biochemical and structural studies. Adv 
Cancer Res (2015) 125:71–96. doi:10.1016/bs.acr.2014.10.003 
82. Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ. 
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies 
in mdr1a knockout mice. Epilepsy Behav (2002) 3:427–32. doi:10.1016/
S1525-5050(02)00511-5 
83. Ashraf T, Kao A, Bendayan R. Functional expression of drug transporters in 
glial cells: potential role on drug delivery to the CNS. Adv Pharmacol (2014) 
71:45–111. doi:10.1016/bs.apha.2014.06.010 
84. van Vliet E, Aronica E, Redeker S, Marchi N, Rizzi M, Vezzani A, et  al. 
Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein 
in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res (2004) 
60:203–13. doi:10.1016/j.eplepsyres.2004.06.005 
85. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, et al. Substrates and 
inhibitors of human multidrug resistance associated proteins and the 
implications in drug development. Curr Med Chem (2008) 15:1981–2039. 
doi:10.2174/092986708785132870 
86. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance 
for pathophysiology and drug therapy. Handb Exp Pharmacol (2011) 
201:299–323. doi:10.1007/978-3-642-14541-4_8 
87. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, 
et al. Expression and immunolocalization of the multidrug resistance pro-
teins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience (2004) 
129:349–60. doi:10.1016/j.neuroscience.2004.07.051 
88. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, 
van Vliet EA, et al. Expression and cellular distribution of multidrug resis-
tance-related proteins in the hippocampus of patients with mesial temporal 
lobe epilepsy. Epilepsia (2004) 45:441–51. doi:10.1111/j.0013-9580.2004. 
57703.x 
89. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, 
et al. Localization of breast cancer resistance protein (BCRP) in microves-
sel endothelium of human control and epileptic brain. Epilepsia (2005) 
46:849–57. doi:10.1111/j.1528-1167.2005.66604.x 
90. Liu JY, Thom M, Catarino CB, Martinian L, Figarella-Branger D, 
Bartolomei F, et  al. Neuropathology of the blood-brain barrier and phar-
maco-resistance in human epilepsy. Brain (2012) 135:3115–33. doi:10.1093/
brain/aws147 
91. Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Leenstra S, 
et al. Expression and cellular distribution of multidrug transporter proteins 
in two major causes of medically intractable epilepsy: focal cortical dysplasia 
and glioneuronal tumors. Neuroscience (2003) 118:417–29. doi:10.1016/
S0306-4522(02)00992-2 
92. Vogelgesang S, Kunert-Keil C, Cascorbi I, Mosyagin I, Schroder E, 
Runge U, et  al. Expression of multidrug transporters in dysembryoplastic 
neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol (2004) 
23:223–31. 
93. Ak H, Ay B, Tanriverdi T, Sanus GZ, Is M, Sar M, et  al. Expression and 
cellular distribution of multidrug resistance-related proteins in patients 
with focal cortical dysplasia. Seizure (2007) 16:493–503. doi:10.1016/j.
seizure.2007.03.011 
94. Sun Y, Luo X, Yang K, Sun X, Li X, Zhang C, et al. Neural overexpression 
of multidrug resistance-associated protein 1 and refractory epilepsy: a 
meta-analysis of nine studies. Int J Neurosci (2016) 126:308–17. doi:10.3109/ 
00207454.2015.1015724 
95. Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Cross JH, Scheper RJ, 
et al. Major vault protein, a marker of drug resistance, is upregulated in refrac-
tory epilepsy. Epilepsia (2003) 44:1388–96. doi:10.1046/j.1528-1157.2003. 
21803.x 
96. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs 
by P-glycoprotein. Adv Drug Deliv Rev (2012) 64:930–42. doi:10.1016/j.
addr.2011.12.003 
97. Syvanen S, Eriksson J. Advances in PET imaging of P-glycoprotein function 
at the blood-brain barrier. ACS Chem Neurosci (2013) 4:225–37. doi:10.1021/
cn3001729 
98. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, 
et  al. Pharmacoresistance in epilepsy: a pilot PET study with the 
P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 48:1774–84. 
doi:10.1111/j.1528-1167.2007.01116.x 
99. Feldmann M, Asselin MC, Liu J, Wang S, McMahon A, Anton-Rodriguez J, 
et al. P-glycoprotein expression and function in patients with temporal lobe 
epilepsy: a case-control study. Lancet Neurol (2013) 12:777–85. doi:10.1016/
S1474-4422(13)70109-1 
100. Shin JW, Chu K, Shin SA, Jung KH, Lee ST, Lee YS, et al. Clinical applica-
tions of simultaneous PET/MR imaging using (R)-[11C]-verapamil with 
cyclosporin A: preliminary results on a surrogate marker of drug-resistant 
epilepsy. AJNR Am J Neuroradiol (2016) 37:600–6. doi:10.3174/ajnr. 
A4566 
101. Zhang C, Kwan P, Zuo Z, Baum L. In vitro concentration dependent 
transport of phenytoin and phenobarbital, but not ethosuximide, by human 
P-glycoprotein. Life Sci (2010) 86:899–905. doi:10.1016/j.lfs.2010.04.008 
102. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, et al. Limbic 
seizures induce P-glycoprotein in rodent brain: functional implications for 
pharmacoresistance. J Neurosci (2002) 22:5833–9. 
103. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux 
of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: 
evidence from microdialysis experiments in rats. Neurosci Lett (2002) 
327:173–6. doi:10.1016/S0304-3940(02)00423-8 
104. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Quantitative in vivo 
microdialysis study on the influence of multidrug transporters on the blood-
brain barrier passage of oxcarbazepine: concomitant use of hippocampal 
monoamines as pharmacodynamic markers for the anticonvulsant activity. 
J Pharmacol Exp Ther (2005) 314:725–31. doi:10.1124/jpet.105.085514 
105. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. 
Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 
(2001) 51:345–9. doi:10.1046/j.1365-2125.2001.01359.x 
106. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug 
resistance-associated protein are involved in the regulation of extracellular 
levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 
(2001) 12:3557–60. doi:10.1097/00001756-200111160-00037 
107. Potschka H, Baltes S, Loscher W. Inhibition of multidrug transporters by 
verapamil or probenecid does not alter blood-brain barrier penetration 
of levetiracetam in rats. Epilepsy Res (2004) 58:85–91. doi:10.1016/j.
eplepsyres.2003.12.007 
108. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not 
a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a 
18
Tang et al. Drug Resistance in Epilepsy
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 301
number of in vitro and in vivo transport assays. J Pharmacol Exp Ther (2007) 
320:331–43. doi:10.1124/jpet.106.102491 
109. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. 
Differences in the transport of the antiepileptic drugs phenytoin, levetira ce-
tam and carbamazepine by human and mouse P-glycoprotein. Neurophar-
ma cology (2007) 52:333–46. doi:10.1016/j.neuropharm.2006.07.038 
110. Luna-Tortós C, Fedrowitz M, Loscher W. Several major antiepileptic 
drugs are substrates for human P-glycoprotein. Neuropharmacology (2008) 
55:1364–75. doi:10.1016/j.neuropharm.2008.08.032 
111. Luna-Tortós C, Rambeck B, Jurgens UH, Loscher W. The antiepileptic 
drug topiramate is a substrate for human P-glycoprotein but not multidrug 
resistance proteins. Pharm Res (2009) 26:2464–70. doi:10.1007/s11095- 
009-9961-8 
112. Luna-Tortós C, Fedrowitz M, Loscher W. Evaluation of transport of common 
antiepileptic drugs by human multidrug resistance-associated proteins 
(MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. 
Neuropharmacology (2010) 58:1019–32. doi:10.1016/j.neuropharm.2010. 
01.007 
113. Verbeek J, Eriksson J, Syvanen S, Labots M, de Lange EC, Voskuyl RA, et al. 
[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first 
evaluation as a P-gp tracer in rats. EJNMMI Res (2012) 2:36. doi:10.1186/ 
2191-219X-2-36 
114. Mairinger S, Bankstahl JP, Kuntner C, Römermann K, Bankstahl M, 
Wanek T, et al. The antiepileptic drug mephobarbital is not transported by 
P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: 
a positron emission tomography study. Epilepsy Res (2012) 100:93–103. 
doi:10.1016/j.eplepsyres.2012.01.012 
115. Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, et  al. A pilot 
study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy- 
5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in 
epilepsy patients not responding to oxcarbazepine. Epilepsia (2005) 
46:1613–9. doi:10.1111/j.1528-1167.2005.00265.x 
116. Potschka H, Loscher W. Multidrug resistance-associated protein is involved 
in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 
(2001) 12:2387–9. doi:10.1097/00001756-200111160-00037 
117. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 
contributes to blood-brain barrier function and restricts antiepileptic 
drug activity. J Pharmacol Exp Ther (2003) 306:124–31. doi:10.1124/
jpet.103.049858 
118. Chen YH, Wang CC, Xiao X, Wei L, Xu G. Multidrug resistance-associated 
protein 1 decreases the concentrations of antiepileptic drugs in cortical extra-
cellular fluid in amygdale kindling rats. Acta Pharmacol Sin (2013) 34:473–9. 
doi:10.1038/aps.2012.183 
119. Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, 
Elmquist WF, et  al. Expression of multidrug resistance-associated protein 
(MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 
(1998) 243:816–20. doi:10.1006/bbrc.1997.8132 
120. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein 
and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm 
Des (2011) 17:2793–802. doi:10.1007/s11307-010-0313-1 
121. Römermann K, Helmer R, Loscher W. The antiepileptic drug lamotrigine is 
a substrate of mouse and human breast cancer resistance protein (ABCG2). 
Neuropharmacology (2015) 93:7–14. doi:10.1016/j.neuropharm.2015.01.015 
122. Cerveny L, Pavek P, Malakova J, Staud F, Fendrich Z. Lack of interactions 
between breast cancer resistance protein (bcrp/abcg2) and selected antie-
pileptic agents. Epilepsia (2006) 47:461–8. doi:10.1111/j.1528-1167.2006. 
00453.x 
123. Nakanishi H, Yonezawa A, Matsubara K, Yano I. Impact of P-glycoprotein 
and breast cancer resistance protein on the brain distribution of antiepi-
leptic drugs in knockout mouse models. Eur J Pharmacol (2013) 710:20–8. 
doi:10.1016/j.ejphar.2013.03.049 
124. Potschka H. Modulating P-glycoprotein regulation: future perspectives for 
pharmacoresistant epilepsies? Epilepsia (2010) 51:1333–47. doi:10.1111/ 
j.1528-1167.2010.02585.x 
125. Bankstahl JP, Loscher W. Resistance to antiepileptic drugs and expression of 
P-glycoprotein in two rat models of status epilepticus. Epilepsy Res (2008) 
82:70–85. doi:10.1016/j.eplepsyres.2008.07.007 
126. van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA. Expression 
of multidrug transporters MRP1, MRP2, and BCRP shortly after status 
epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 
(2005) 46:1569–80. doi:10.1111/j.1528-1167.2005.00250.x 
127. Pardridge WM. Blood-brain barrier genomics and the use of endogenous 
transporters to cause drug penetration into the brain. Curr Opin Drug Discov 
Devel (2003) 6:683–91. 
128. Seegers U, Potschka H, Loscher W. Lack of effects of prolonged treatment 
with phenobarbital or phenytoin on the expression of P-glycoprotein in 
various rat brain regions. Eur J Pharmacol (2002) 451:149–55. doi:10.1016/
S0014-2999(02)02235-5 
129. Wang-Tilz Y, Tilz C, Wang B, Tilz GP, Stefan H. Influence of lamotrigine and 
topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. 
Epilepsia (2006) 47:233–9. doi:10.1111/j.1528-1167.2006.00414.x 
130. Potschka H, Volk HA, Loscher W. Pharmacoresistance and expression of 
multidrug transporter P-glycoprotein in kindled rats. Neuroreport (2004) 
15:1657–61. doi:10.1097/01.wnr.0000134840.10390.a4 
131. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-
induced up-regulation of P-glycoprotein at the blood-brain barrier 
through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol (2008) 
73:1444–53. doi:10.1124/mol.107.041210 
132. Wen T, Liu YC, Yang HW, Liu HY, Liu XD, Wang GJ, et al. Effect of 21-day 
exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein 
expression and activity in the rat brain. J Neurol Sci (2008) 270:99–106. 
doi:10.1016/j.jns.2008.02.016 
133. Ambroziak K, Kuteykin-Teplyakov K, Luna-Tortós C, Al-Falah M, 
Fedrowitz M, Loscher W. Exposure to antiepileptic drugs does not alter the 
functionality of P-glycoprotein in brain capillary endothelial and kidney cell 
lines. Eur J Pharmacol (2010) 628:57–66. doi:10.1016/j.ejphar.2009.11.051 
134. Lazarowski A, Ramos AJ, Garcia-Rivello H, Brusco A, Girardi E. Neuronal 
and glial expression of the multidrug resistance gene product in an exper-
imental epilepsy model. Cell Mol Neurobiol (2004) 24:77–85. doi:10.1023/
B:CEMN.0000012726.43842.d2 
135. Hocht C, Lazarowski A, Gonzalez NN, Auzmendi J, Opezzo JA, 
Bramuglia GF, et al. Nimodipine restores the altered hippocampal phenytoin 
pharmacokinetics in a refractory epileptic model. Neurosci Lett (2007) 
413:168–72. doi:10.1016/j.neulet.2006.11.075 
136. Enrique A, Goicoechea S, Castano R, Taborda F, Rocha L, Orozco S, et al.  
New model of pharmacoresistant seizures induced by 3-mercaptopropi-
onic acid in mice. Epilepsy Res (2017) 129:8–16. doi:10.1016/j.eplepsyres. 
2016.10.012 
137. Hartz AM, Notenboom S, Bauer B. Signaling to P-glycoprotein-A new ther-
apeutic target to treat drug-resistant epilepsy? Drug News Perspect (2009) 
22:393–7. doi:10.1358/dnp.2009.22.7.1401354 
138. Pekcec A, Unkruer B, Schlichtiger J, Soerensen J, Hartz AM, Bauer B, 
et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated 
P-glycoprotein up-regulation. J Pharmacol Exp Ther (2009) 330:939–47. 
doi:10.1124/jpet.109.152520 
139. Zibell G, Unkruer B, Pekcec A, Hartz AM, Bauer B, Miller DS, et  al. 
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein 
by COX-2 inhibition. Neuropharmacology (2009) 56:849–55. doi:10.1016/j.
neuropharm.2009.01.009 
140. Salvamoser JD, Avemary J, Luna-Munguia H, Pascher B, Getzinger T, 
Pieper T, et  al. Glutamate-mediated down-regulation of the multidrug- 
resistance protein BCRP/ABCG2 in porcine and human brain capillaries. 
Mol Pharm (2015) 12:2049–60. doi:10.1021/mp500841w 
141. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, 
et  al. Functional polymorphisms of the human multidrug-resistance 
gene: multiple sequence variations and correlation of one allele with 
P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 
97:3473–8. doi:10.1073/pnas.97.7.3473 
142. Kwan P, Wong V, Ng PW, Lui CH, Sin NC, Poon WS, et  al. Gene-wide 
tagging study of association between ABCB1 polymorphisms and multidrug 
resistance in epilepsy in Han Chinese. Pharmacogenomics (2009) 10:723–32. 
doi:10.2217/pgs.09.32 
143. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype 
and PGP expression, function and therapeutic drug response: a critical 
review and recommendations for future research. Pharmacogenomics J 
(2007) 7:154–79. doi:10.1038/sj.tpj.6500413 
144. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, 
et al. The effects of the human MDR1 genotype on the expression of duodenal 
19
Tang et al. Drug Resistance in Epilepsy
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 301
P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol 
Ther (2002) 72:572–83. doi:10.1067/mcp.2002.127739 
145. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, 
et  al. Failure to confirm association of a polymorphism in ABCB1 with 
multidrug-resistant epilepsy. Neurology (2004) 63:1090–2. doi:10.1212/01.
WNL.0000137051.33486.C7 
146. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, et  al.  
Lack of association between the C3435T polymorphism in the human 
multidrug resistance (MDR1) gene and response to antiepileptic drug 
treatment. Epilepsia (2005) 46:643–7. doi:10.1111/j.1528-1167.2005.46304.x 
147. Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between 
C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant 
epilepsy. Seizure (2006) 15:344–7. doi:10.1016/j.seizure.2006.02.015 
148. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, 
et al. The controversial association of ABCB1 polymorphisms in refractory 
epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res 
(2007) 73:192–8. doi:10.1016/j.eplepsyres.2006.10.004 
149. Leschziner GD, Andrew T, Leach JP, Chadwick D, Coffey AJ, Balding DJ, 
et al. Common ABCB1 polymorphisms are not associated with multidrug 
resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet 
Genomics (2007) 17:217–20. doi:10.1097/01.fpc.0000230408.23146.b1 
150. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. 
Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resis-
tance to anticonvulsant drugs: a meta-analysis. Epilepsia (2009) 50:898–903. 
doi:10.1111/j.1528-1167.2008.01858.x 
151. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, et  al. 
ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic 
drugs in epilepsy: a systematic review and meta-analysis. Seizure (2010) 
19:339–46. doi:10.1016/j.seizure.2010.05.004 
152. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of 
ABCB1 gene polymorphisms and their haplotypes with response to antie-
pileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 
(2011) 12:713–25. doi:10.2217/pgs.10.212 
153. Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, 
Siegmund W, et  al. Association of ABCB1 genetic variants 3435C>T and 
2677G>T to ABCB1 mRNA and protein expression in brain tissue from 
refractory epilepsy patients. Epilepsia (2008) 49:1555–61. doi:10.1111/ 
j.1528-1167.2008.01661.x 
154. Grover S, Kukreti R. A systematic review and meta-analysis of the role of 
ABCC2 variants on drug response in patients with epilepsy. Epilepsia (2013) 
54:936–45. doi:10.1111/epi.12132 
155. Qian L, Fang S, Yan YL, Zeng SS, Xu ZJ, Gong ZC. The ABCC2 c.-24C>T 
polymorphism increases the risk of resistance to antiepileptic drugs: a 
meta-analysis. J Clin Neurosci (2017) 37:6–14. doi:10.1016/j.jocn.2016.10.014 
156. Chen P, Yan Q, Xu H, Lu A, Zhao P. The effects of ABCC2 G1249A poly-
morphism on the risk of resistance to antiepileptic drugs: a meta-analysis 
of the literature. Genet Test Mol Biomarkers (2014) 18:106–11. doi:10.1089/
gtmb.2013.0362 
157. Wang Y, Tang L, Pan J, Li J, Zhang Q, Chen B. The recessive model of MRP2 
G1249A polymorphism decrease the risk of drug-resistant in Asian Epilepsy: 
a systematic review and meta-analysis. Epilepsy Res (2015) 112:56–63. 
doi:10.1016/j.eplepsyres.2015.02.007 
158. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp 
inhibitors: skimming through several generations and scaffolds. Curr Med 
Chem (2012) 19:1946–2025. doi:10.2174/092986712800167392 
159. Munagala S, Sirasani G, Kokkonda P, Phadke M, Krynetskaia N, Lu P, et al. 
Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for 
cancer cell eradication. Bioorg Med Chem (2014) 22:1148–55. doi:10.1016/j.
bmc.2013.12.022 
160. Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential 
P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharma-
cother (2004) 38:1631–4. doi:10.1345/aph.1E068 
161. Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil admini-
stration in prolonged and refractory status epilepticus. Epilepsia (2005) 
46:967–9. doi:10.1111/j.1528-1167.2005.59204.x 
162. Pirker S, Baumgartner C. Termination of refractory focal status epilepticus 
by the P-glycoprotein inhibitor verapamil. Eur J Neurol (2011) 18:e151. 
doi:10.1111/j.1468-1331.2011.03513.x 
163. Asadi-Pooya AA, Razavizadegan SM, Abdi-Ardekani A, Sperling MR. 
Adjunctive use of verapamil in patients with refractory temporal lobe 
epilepsy: a pilot study. Epilepsy Behav (2013) 29:150–4. doi:10.1016/j.
yebeh.2013.07.006 
164. Borlot F, Wither RG, Ali A, Wu N, Verocai F, Andrade DM. A pilot dou-
ble-blind trial using verapamil as adjuvant therapy for refractory seizures. 
Epilepsy Res (2014) 108:1642–51. doi:10.1016/j.eplepsyres.2014.08.009 
165. Narayanan J, Frech R, Walters S, Patel V, Frigerio R, Maraganore DM. Low 
dose verapamil as an adjunct therapy for medically refractory epilepsy – an 
open label pilot study. Epilepsy Res (2016) 126:197–200. doi:10.1016/j.
eplepsyres.2016.07.004 
166. Loscher W, Langer O. Imaging of P-glycoprotein function and expression 
to elucidate mechanisms of pharmacoresistance in epilepsy. Curr Top Med 
Chem (2010) 10:1785–91. doi:10.2174/156802610792928095 
167. Cascorbi I. ABC transporters in drug-refractory epilepsy: limited clinical 
significance of pharmacogenetics? Clin Pharmacol Ther (2010) 87:15–8. 
doi:10.1038/clpt.2009.237 
168. Bauer M, Karch R, Zeitlinger M, Liu J, Koepp MJ, Asselin MC, et al. In vivo 
P-glycoprotein function before and after epilepsy surgery. Neurology (2014) 
83:1326–31. doi:10.1212/WNL.0000000000000858 
169. Engel J, Wiebe S, French J, Sperling M, Williamson P, Spencer D, et  al. 
Practice parameter: temporal lobe and localized neocortical resections for 
epilepsy: report of the Quality Standards Subcommittee of the American 
Academy of Neurology, in Association with the American Epilepsy Society 
and the American Association of Neurological Surgeons. Neurology (2003) 
60:538–47. doi:10.1212/01.WNL.0000055086.35806.2D
170. Morris  GL III, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. 
Evidence-based guideline update: vagus nerve stimulation for the treatment 
of epilepsy: report of the Guideline Development Subcommittee of the 
American Academy of Neurology. Neurology (2013) 81:1453–9. doi:10.1212/
WNL.0b013e3182a393d1 
171. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: 
challenges, incentives, and recent advances. Lancet Neurol (2007) 6:793–804. 
doi:10.1016/S1474-4422(07)70215-6 
172. Sorensen AT, Kokaia M. Novel approaches to epilepsy treatment. Epilepsia 
(2013) 54:1–10. doi:10.1111/epi.12000 
173. Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-
associated virus-based gene therapy for CNS diseases. Hum Gene Ther (2016) 
27:478–96. doi:10.1089/hum.2016.087 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Tang, Hartz and Bauer. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
